

Author Index to CGC Volumes 65-71

- A
 Abdelhay E, 71:173
 Abe S, 66:135
 Abe Y, 66:103
 Abeliovich D, 70:117
 Abramova E, 68:52
 Advani SH, 66:43
 Ajmar F, 67:50
 Al Aasar EM, 68:147
 Al-Bahar S, 68:147
 Al-Katib A, 70:62
 Alers J, 66:131
 Alfinito F, 69:136
 Alimena G, 66:39
 Allen EF, 71:102
 Alm P, 65:79
 Altman AJ, 67:81
 Alvarez A, 70:153
 Alvarez MA, 65:76
 Aly MS, 65:104
 Amadori D, 65:111
 Ambros PF, 71:94
 Amiel A, 65:32; 70:21
 Anderson JR, 69:79
 Andria M, 68:32
 Angelucci D, 70:151
 Antinolo G, 65:177; 71:183
 Antonini P, 67:117
 Antonucci A, 65:88
 Ardisia C, 67:113
 Argyriou-Tirita A, 71:50
 Arioka H, 71:22
 Arps S, 66:93
 Asenjo S, 70:153
 Asensio A, 65:170; 70:152
 Atkin NB, 67:123
 Auamatsu T, 71:155
 Avalos MR, 66:70
 Ayraud N, 67:149; 71:100
- B
 Babacan E, 69:38
 Badia L, 65:76
 Baens M, 69:60
 Baer MR, 67:141
 Bajer J, 65:115
 Baker MC, 67:123
 Balsara B, 66:43
 Barbata G, 66:63
 Barbieri-Neto J, 69:146
 Bardi A, 71:119
 Barnes L, 65:21
- Bartelt D Jr, 71:76
 Bartnitzke S, 65:27; 65:64;
 67:90; 69:68
 Bartsch O, 71:67
 Basso G, 71:144
 Bauduer F, 69:156
 Bayle J, 71:100
 Beck WT, 70:48
 Beitzel BF, 71:125
 Bello MJ, 66:1; 66:28;
 66:117; 71:185
 Ben-Neriah S, 70:117
 Benkhalifa M, 67:101
 Benn PA, 67:81
 Berger CS, 70:103; 70:132
 Berger R, 65:47; 66:128;
 66:137; 67:117; 69:13;
 70:125; 70:146
 Bernheim A, 66:11
 Bernus M, 69:76
 Besses C, 65:170; 69:165;
 70:152
 Bettio D, 68:149
 Beverstock GC, 65:7
 Bharadwaj TPR, 65:12
 Bhatia PS, 69:79
 Birch JM, 67:108; 67:133
 Bixenman HA, 71:27
 Bjerre P, 69:118
 Blij-Philipsen Mvd, 71:178
 Blin N, 70:108
 Block AM, 71:105
 Block AW, 67:141
 Bohjanen PR, 68:34
 Bohling T, 65:141; 68:1
 Bohm M, 65:83
 Bokesoy I, 69:38
 Bolcato S, 71:144
 Bolle J-F, 65:58
 Bolund L, 66:16
 Bonet C, 69:165
 Bonk U, 65:64; 69:68
 Booker SV, 67:14
 Borrego S, 65:177; 71:183
 Bosman FT, 67:35
 Bouchot C, 67:149
 Bown NP, 69:166
 Brandi M-L, 70:68
 Brennan H, 69:41
 Breschi C, 67:113
 Bressel M, 66:93
 Bridge JA, 67:145; 69:79
- Brock P, 65:104
 Browett PJ, 70:142
 Bruner B, 71:100
 Bruzzzone R, 67:50
 Bubanska E, 71:67
 Bull RM, 67:136
 Bullerdiek J, 65:27; 65:64;
 67:90; 69:68
 Bussel A, 70:125
 Busson P, 66:11
 Butler MG, 66:108;
 71:132
 Buzzi M, 67:55
- C
 Caballin MR, 69:76
 Cabello P, 66:126; 69:74
 Caillou B, 67:117
 Calabrese G, 65:88; 70:151
 Calin G, 70:71
 Capra E, 68:140
 Caradonna F, 66:63; 66:77
 Carbone P, 66:63; 66:77
 Cardoso H, 68:122
 Carl P, 66:93
 Carli M, 71:144
 Carli MG, 71:119
 Carneiro F, 68:42
 Caronia F, 66:77
 Carpenter PM, 69:65
 Carroll AJ, 68:34
 Casadevall C, 69:76
 Casalone R, 68:126
 Casartelli C, 69:146
 Cassiman J-J, 69:60
 Castedo S, 67:1; 68:42;
 69:31
 Casteels-Van Daele M,
 65:104
 Castoldi G, 71:119
 Catalono L, 69:136
 Cavalli IJ, 68:82
 Cavdar AO, 69:38
 Cedrone M, 66:39
 Cepulic M, 65:167
 Cerd-Nicols M, 65:173;
 70:74
 Chaganti RSK, 69:17
 Champlin R, 65:100
 Chan AYY, 65:74
 Chan-Lam D, 70:144
 Chan LC, 65:74; 66:79;
 69:139; 69:158;
 69:163; 70:155
 Chandy M, 65:12
 Ch'ang H-J, 71:87
 Charbonne F, 67:101
 Chaves H, 69:141
 Chen D-S, 65:161
 Chen H-L, 65:161
 Chen P-J, 65:161
 Chen R-L, 69:25
 Chen YC, 71:87
 Chen Z, 66:73; 70:103;
 70:125
 Cheng PNM, 70:155
 Chiamenti A, 67:50
 Chiaravalli AM, 68:126
 Chilla R, 65:27
 Chiu T-S, 65:161
 Christensen ER, 71:7
 Chuang S-M, 69:25; 71:87
 Ciccone G, 68:135
 Cleaver G, 67:150
 Clode A, 67:1
 Cochrane DD, 71:40
 Coindre J-M, 66:133;
 67:149
 Colita D, 70:71
 Collin F, 66:133
 Colozza MA, 67:113
 Conic S, 68:78
 Copplestone JA, 70:144
 Cork A, 65:100
 Correia C, 68:42; 69:31
 Corson JM, 66:100
 Cortinovis M, 70:68
 Cotter PD, 70:142
 Couzigou P, 67:7
 Craig J, 65:93
 Cremer T, 70:99
 Crist WM, 68:34
 Crossen PE, 69:72
 Cuneo A, 71:119
 Czepulkowski B, 65:51
- D
 Dadoune J-P, 69:156
 Dahir GA, 66:108; 71:132
 Dahl RJ, 67:21, 71:76
 Dainotti E, 70:68
 Dal Cin P, 65:104; 68:32;
 68:85; 71:170
 Dallapiccola B, 67:28

- Daniel M-T, 70:146
 Danks MK, 70:48
 Dastugue N, 67:101
 Davare J, 67:79
 Davico L, 68:135
 Davies SV, 71:148
 Davis S, 67:113
 De Bellis R, 68:122
 De Busscher C, 68:74
 de Campos JM, 66:1; 66:28;
 66:117; 71:185
 De Cuia MR, 66:39
 de Graaff WE, 70:12
 de Jong B, 68:42; 70:12;
 70:85
 de Jong PJ, 65:93
 de Leeuw B, 71:164
 de los Angeles Mori M,
 68:122
 de Souza MHO, 71:173
 de Vries JE, 67:35
 De Wever I, 65:104; 68:85
 Deerbeg J, 68:91
 Defferrari R, 67:50
 Degen DR, 65:120
 Deisseroth A, 65:100
 Del Poeta G, 67:28
 del Rosario Uriarte M,
 68:122
 Delaroche I, 67:28
 Delmas-Marsalet B, 69:156
 Delmer A, 69:156
 Delozier-Blanchet CD,
 65:58
 Deminatti M-M, 65:175
 den Ottolander GJ, 65:7
 Dennis T, 66:47
 Deprest J, 68:32
 Devaraj J, 70:136
 Devriendt K, 65:104
 Dewald GW, 68:60; 71:7
 Di Bartolomeo P, 65:88
 Dickman PS, 65:152
 Diehl SR, 65:68
 Diehl V, 67:90
 Dietrich CU, 69:118
 Dobbs RM, 65:1
 Dobrovic A, 69:122
 Dofuku R, 69:100
 Dohy H, 70:39
 Doles J, 65:130
 Dommergues JP, 66:70
 Donovan K, 66:100
 Donti E, 67:113
 Dooley TP, 71:55
 Drabek SM, 65:120;
 71:125
 Drabkin H, 71:15
 Dumas F, 67:7
 Dutrillaux B, 69:161
- E
 Egozcue J, 69:76
 Elner VM, 66:47
 Elomaa I, 65:141; 68:1
 Enokihara H, 68:95
 Epping A, 68:78
- F
 Fabbiano F, 66:77
 Fagan K, 65:71
 Fagioli F, 71:119
 Farabegoli P, 67:55
 Feiden W, 71:151
 Fejgin M, 65:32; 70:21
 Fenaux P, 65:175
 Ferrari L, 71:119
 Ferro MT, 69:74;
 70:153
 Ferro T, 66:126
 Fett-Conte AC, 69:141
 Feusner J, 69:153
 Fibbe WE, 65:7
 Fiedler W, 68:49
 Flactif M, 65:175
 Fletcher JA, 66:100
 Florensa L, 65:170;
 69:165; 70:152
 Fossion E, 71:170
 Fraccaro M, 70:68
 Franchi PG, 65:88
 Friberg L-G, 65:35
 Fu S-B, 69:91
 Fugazza G, 67:50
 Fujimura T, 68:143
 Furuta K, 71:155
 Furuta S, 68:95;
 71:155
 Furuya T, 70:132
 Fusaro RM, 71:27
- G
 Gaber E, 65:32; 70:21
 Gardner H, 71:94
 Gaillard N, 67:117
 Garcia-Sagredo JM,
 66:126; 69:74
 Gavarotti P, 68:135
 Geissler K, 71:50
 Gelabert A, 69:76
 Gemmill R, 71:15
 Gendron M-C, 69:13
 Georgii A, 66:130
 Geraedts J, 70:56
 Geraedts JPM, 67:35
 Geraghty MT, 71:164
 Gerald W, 69:17
 Giardiello FM, 67:14
 Giardino D, 68:149
 Giraud B, 67:101
- Gladstone B, 66:43
 Glukhova LA, 65:147
 Goddard K, 71:40
 Gollin SM, 65:21; 65:152
 Gomes P, 67:1; 68:42;
 69:31
 Gonzalez FA, 70:153
 Gordon RD, 68:78
 Goto T, 66:103
 Goussot J-F, 67:7
 Govaerts LCP, 71:178
 Gozdasoglu S, 69:38
 Grabovskaya IL, 65:147
 Granata G, 66:63
 Granata P, 68:126
 Granberg S, 65:35
 Griffin CA, 65:135; 67:14
 Grois N, 71:50
 Grote W, 68:91
 GU J, 69:51
 Guo Y, 65:157; 69:51
 Gutman M, 65:111
- H
 Ha SY, 66:79; 69:139
 Haas OA, 70:112; 71:50
 Haddad FS, 71:105
 Hagemeijer A, 65:125
 Hallman H, 70:120
 Hambræus G, 66:33
 Hamilton SR, 67:14
 Han K, 68:99
 Hannan MA, 66:120
 Hanson CA, 68:34
 Hansteen I-L, 70:94
 Hara H, 70:77
 Harbott J, 68:131
 Harris CP, 68:99
 Harris M, 67:133
 Harrison P, 65:71
 Harthoorn-Lasthuizen EJ,
 71:178
 Hartley AL, 67:133
 Hartmann L, 71:76
 Hashimoto T, 70:39
 Hast R, 70:79
 Haubrich J, 65:27
 Haugen A, 70:94
 Haus O, 67:101
 Hawkins JM, 70:148
 He Z, 65:157
 Hecht BK, 67:147; 70:81
 Hecht F, 67:147; 70:81
 Heerema NA, 68:114;
 70:148
 Hegewisch-Becker S, 68:49
 Heim S, 65:79; 66:33;
 69:118
 Heimann P, 68:74
- Heinonen K, 68:104;
 70:120
 Helio H, 65:141; 68:1
 Henn W, 71:151
 Henske E, 65:100
 Herrmann ME, 67:44
 Hertz JM, 66:16
 Herzog R, 70:108
 Hilgers J, 69:100
 Hill AB, 70:48
 Hillion J, 70:125
 Hilt B, 70:94
 Himmelmann A, 65:79
 Hirai H, 69:113
 Hirata J, 65:107; 66:103
 Hirst WJR, 65:51
 Hollstein M, 65:111
 Hopman A, 70:56; 71:97
 Hossfeld DK, 68:49; 70:1;
 70:140; 71:180
 Houldsworth J, 65:111
 Howell RT, 70:144
 Huben RP, 71:105
 Huffermann K, 66:133
 Hukku B, 68:22
 Hyde S, 65:71
- I
 Iosif S, 65:79
 Ishida F, 68:95
 Ishiguro M, 70:77
 Ishikawa Y, 71:22
 Islam MQ, 65:35
 Ito H, 67:71
 Iwabuchi A, 67:71;
 68:143
 Iwasaki H, 70:77
- J
 Jalal SM, 68:60; 71:7
 Jambekar NA, 66:43
 Janecka I, 65:21
 Janssen HAP, 71:164
 Janvier D, 70:125
 Jauch A, 70:99
 Jawadi NS, 70:62
 Jelinek J, 71:67
 Jenkins RB, 67:21; 71:76
 Jenks HM, 65:125
 Jensen MP, 66:16
 Jhanwar SC, 69:1
 Jimenez F, 65:177
 Johansson B, 70:6
 Johansson L, 66:33
 Johansson M, 66:33
 Johnsen LR, 71:27
 Jones PHM, 67:133
 Jonveaux P, 66:128;
 70:146

- Joseph A, 71:15
Jox A, 67:90
- K
Kadam PR, 66:43
Kaipainen A, 65:141; 68:1
Kakati S, 67:141
Kalatzis V, 69:122
Kalousek DK, 71:40
Kamada N, 65:12; 70:39
Kaneko Y, 70:17; 70:77
Kangwanpong D, 69:129
Karaharju E, 65:141; 68:1
Kashimura M, 65:81
Kastendieck H, 66:93
Katsuyama T, 71:155
Kavallaris M, 66:54
Kawakubo K, 68:143
Kawano F, 71:71
Kawasaki S, 71:155
Kearsley JH, 67:65
Keeney G, 71:76
Kelsey AM, 67:133
Kikuchi M, 70:77
Kim S, 68:34
Kimmel DW, 67:21
Kitano K, 68:95; 71:155
Kitchen C, 70:144
Kivioja A, 68:1
Kiyosawa K, 71:155
Klemm SA, 68:78
Klempnauer J, 66:130
Knuutila S, 65:141; 68:1;
68:104; 70:120; 71:15
Kobayashi H, 68:95
Kobayashi R, 71:22
Koch B, 69:126
Kodama A, 68:143
Kohls S, 67:90
Konja J, 65:167
Kools P, 68:85
Kopfl, 65:35
Kornips FHAC, 67:35
Krous HF, 69:65
Krsnik I, 66:126
Krush AJ, 67:14
Kusak ME, 66:1; 66:28;
66:117; 71:185
Kushch AA, 65:147
Kwong YL, 65:74; 66:79;
69:139; 69:158;
69:163
- L
Ladenstein R, 71:94
Lai J-L, 65:175
Lalkin A, 70:21
Lalley PA, 67:44
Lampert F, 68:131
Landegent JE, 65:7
Larramendy M, 68:104
Larramendy ML, 70:120
Laurent-Puig P, 69:161
Lazar S, 67:14
Le Coniat M, 65:47;
69:13
Leana-Cox J, 70:127
Lee F-Y, 69:25
Lee W, 68:99
Leiden JM, 68:34
Lejeune J, 66:70
Lengauer C, 70:99
Leonard C, 66:70
Leonard JH, 67:65
Leonard P, 67:65
Leone G, 65:115
Leppert M, 71:27
Leseve J-F, 67:7
Leuschner E, 65:64
Levan A, 65:35
Levan G, 65:35
Levis A, 68:135
Li L, 68:131
Li M-J, 69:45
Liang RHS, 66:79
Libert A, 68:74
Lie AKW, 69:158
Liedtke H Jr, 69:141
Lien J T, 70:94
Lilla VC, 68:60
Lin B, 65:157; 69:51
Lin D-T, 71:87
Lin K-H, 69:25; 71:87
Linares G, 67:117
Lindemann U, 69:126
Lishner M, 65:32; 70:21
Liu M-C, 69:25
Liu P, 65:93; 65:100
Liu Q-Z, 69:91
Liu W, 69:139
Llombart-Bosch A,
65:173; 70:74
Locker G, 71:50
Lohmeyer J, 68:131
Long P, 67:14
Longy M, 67:7
Loning T, 71:180
Lopez-Gins C, 65:173;
70:74
Lopez-Yarto A, 69:74
Lowery MC, 67:136
Lu G, 67:81
Lu P, 69:91
Lu Y-J, 69:91
Luciano L, 69:136
Lunde JH, 71:102
Lynch HT, 71:27
Lynch JF, 71:27
- M
Mackie PH, 70:148
Mahlamaki E, 68:104
Makuuchi M, 71:155
Malet P, 67:101
Malkin D, 66:83
Malone PS, 65:21; 65:152
Malvezzi M, 68:82
Mamaeva S, 68:52
Mancini M, 66:39
Mandahl N, 66:33
Mano H, 69:113
Manor A, 65:111
Manor Y, 65:32; 70:21
Mansoor AM, 65:12
Maraschio P, 70:68
Marosi C, 71:50
Marras S, 68:32
Martin N, 68:78
Martin-Noya A, 71:183
Martinelli G, 67:50; 67:55
Marx P, 67:35
Mascarello JT, 69:65
Masi M, 67:28
Massaad L, 66:11
Matsuda I, 70:17
Matsui Y, 70:17
Matsunaga AT, 69:153
Matsunami H, 71:155
Matsuyama T, 70:17
Mattern VL, 71:55
Matzner Y, 70:117
Mazariello YV, 69:74
Mazza G, 66:113
McGill JR, 65:120; 71:125
Meador RJ, 71:125
Mecucci C, 69:60
Meese E, 70:108
Meisner LF, 68:99
Meloni AM, 65:1; 67:59;
67:79; 69:35; 69:132;
70:85; 71:1; 71:105;
71:164
Meltzer SJ, 70:127
Meroni E, 68:126
Mertens F, 70:6
Meyer-Bolte K, 65:27
Micale MA, 69:7
Michalova K, 71:67
Milot F, 66:70
Miesfeldt S, 68:34
Mikuni C, 66:135
Minamihisamatsu M,
65:81
Minelli E, 68:126
Mingarelli R, 67:28
Mirabelli D, 68:135
Mir R, 69:76
Mirto S, 66:77
- Mitani K, 69:113
Mitchell ELD, 67:108
Mitelman F, 65:79; 66:33;
70:6
Miura AB, 71:176
Miura I, 71:176
Miura K, 71:71
Moerman P, 65:104; 68:32
Moertel CA, 67:21
Mohamed AN, 67:44;
70:62
Mohammad RM, 70:62
Monaco AP, 71:164
Monpoux F, 71:100
Montaldi A, 71:144
Montero S, 65:170
Moore CM, 71:55
Moore GE, 69:108
Mor O, 65:111
Morandini R, 68:74
Morgan R, 66:73; 70:103;
70:132
Morizio E, 70:151
Morris M, 65:58
Morrison MJ, 69:72
Morse HG, 69:108
Motoiu I, 70:71
Motzer RJ, 69:17
Mufti GJ, 65:51
Muhm M, 71:50
Muleris M, 69:161
Murthy PBK, 65:12
Müllenbach R, 70:108
Müller-Hermelink A, 68:91
Musolino C, 66:113
- N
Nadeau S, 71:15
Naeem R, 66:100
Nagler A, 65:32
Nair CN, 66:43
Naito H, 71:22
Nakayama J, 71:155
Nakic M, 65:167
Nanba K, 71:155
Nanni M, 66:39
Nawata H, 65:107; 66:103
Neerman-Arbez M, 65:58
Neff JR, 67:145; 69:79
Neri G, 65:115
Neumann E, 71:40
Nicolai M, 70:151
Nicoletti B, 67:28
Nicolo G, 67:149
Nielsen JL, 65:120; 71:125
Nielsen KB, 70:79
Ninfo V, 71:144
Nishimura J, 65:107;
66:103

Nobbs MC, 70:144
 Nolte M, 66:130
 Norman MG, 71:40
 Nylund SJ, 70:120

O

Ogawa S, 69:113
 Oguma N, 70:39
 Ogur G, 68:74
 Ohgami A, 70:77
 Ohjimi Y, 70:77
 Ohyashiki JH, 67:71;
 68:143
 Ohyashiki K, 67:71;
 68:143
 Oosterhuis JW, 70:12;
 70:85
 Ost A, 70:79
 Owade JMN, 68:147
 Ozisik YY, 67:59; 67:79;
 69:35; 69:132; 71:1

P

Paetau A, 68:104
 Pagliaro LC, 67:95
 Palau F, 65:76
 Palka G, 65:88; 70:151
 Palmer CG, 68:114
 Palmer JH, 69:129
 Pamir A, 69:38
 Pandis N, 69:118
 Pandita R, 68:147
 Panzica G, 67:55
 Papa G, 67:28
 Parikh PM, 66:43
 Parmentier C, 67:117
 Parody R, 65:177; 71:183
 Parrington JM, 70:85
 Parshad R, 70:25
 Pasquini R, 68:82
 Pauwels R, 70:56; 71:97
 Paweletz N, 70:31
 Pawlita M, 67:90
 Pearce-Birge L, 70:103
 Pearson ADJ, 69:166
 Pedersen S, 66:16
 Pedetour F, 66:133,
 67:149
 Pehamberger H, 71:50
 Peier AM, 71:105
 Peila R, 65:88
 Pejovic T, 65:79
 Pelliconi S, 67:55
 Pereira MSO, 71:173
 Perissel B, 67:101
 Pernice F, 66:113
 Persons D, 71:76
 Pestaa A, 66:1; 66:28;
 66:117

Peters GB, 69:122
 Petkovic I, 65:167
 Petti MC, 66:39
 Peydro-Olaya A, 65:173;
 70:74
 Pezzolo A, 70:68
 Pfreundschuh M, 69:126
 Philip P, 71:100
 Piantadosi S, 65:135
 Pignatti PF, 67:50
 Pirc-Danoewinata H,
 71:50
 Pittman SM, 66:54
 Piva N, 71:119
 Podratz K, 71:76
 Poissonnier M, 66:70
 Polito P, 69:136
 Pontes JE, 65:1
 Popp S, 70:99
 Porfirio B, 67:113
 Portentos P, 68:126
 Porter PA, 71:55
 Potter W, 71:105
 Powell IJ, 69:7; 71:105
 Powell M, 67:59
 Pozzi E, 68:126
 Pralle H, 68:131
 Prentice HG, 70:148
 Prevati R, 71:119
 Price FM, 70:25
 Prieto F, 65:76
 Provisor AJ, 70:148
 Pushpa V, 65:12

Q

Qureshi F, 69:35

R

Rainho CA, 69:146
 Ramaekers F, 70:56; 71:97
 Ramesh KH, 71:27
 Ramond S, 69:156
 Ranzani GN, 65:111
 Rao SR, 66:43
 Rath F-W, 71:139
 Ratner S, 67:44
 Ravia Y, 65:111
 Ravid M, 70:21
 Raynaud SD, 71:100
 Redman JF, 69:57
 Rege-Cambrin G, 68:135
 Reid MM, 69:166
 Reilly P, 68:114
 Resau J, 69:1
 Resino M, 66:126; 69:74;
 70:153
 Reuter VE, 69:17
 Rey JA, 66:1; 66:28;
 66:117; 71:185

Reynolds JE, 65:68
 Rhim JS, 68:22
 Ribeiro EMSF, 68:82
 Rieck J, 71:180
 Righi R, 68:126
 Rigolin GM, 71:119
 Rindi G, 68:140
 Ritterbach J, 68:131
 Rizzi N, 68:149
 Robichaux W, 65:152
 Robinson ES, 71:55
 Rodewald A, 66:93
 Rodriguez E, 69:17
 Rogatto SR, 69:146
 Rohen C, 69:68
 Roloson GJ, 69:57
 Rondez R, 65:58
 Rondinelli MB, 66:39
 Roozendaal KJ, 65:7
 Roque L, 67:1, 69:31
 Rosenblum-Vos LS,
 70:127
 Rotman G, 65:111
 Rotoli B, 69:136
 Rousselet G, 66:11
 Rowley S, 65:135
 Rutherford JC, 68:78
 Ruutu T, 68:104,
 70:120
 Ryan JR, 69:35
 Rydstedt LL, 67:44

S

Sackey K, 66:120
 Sadamura S, 65:107;
 66:103
 Sainati L, 71:144
 Sait SNJ, 67:141
 Saito H, 68:95
 Saitta A, 66:113
 Sakr WA, 69:7
 Salmon R-J, 69:161
 Salzer-Kuntschik M,
 71:94
 San Roman C, 66:126
 Sanada I, 71:71
 Sandberg AA, 65:1;
 66:73; 67:59; 67:79;
 69:35; 69:132; 70:85;
 70:103; 70:132; 71:1;
 71:27; 71:105; 71:164
 Sanford JS, 69:7
 Sanford KK, 70:25
 Sankary S, 65:21;
 65:152
 Sans-Sabrafen J,
 65:170; 69:165;
 70:152
 Santi G, 68:140
 Santibanez-Koref MF,
 67:108
 Santoro A, 66:77
 Santos G, 65:135
 Saragas E, 66:75
 Sarasa JL, 66:1; 66:117
 Sasso I, 67:71
 Sato H, 65:107; 66:103
 Sato I, 66:135
 Sato M, 71:71
 Sato Y, 69:113
 Saura R, 67:7
 Sawyer JR, 69:57
 Scapinello A, 71:144
 Scappaticci S, 68:140;
 70:68
 Schad CR, 68:60; 71:7
 Schaison G, 65:47
 Schapers R, 70:56; 71:97
 Schapiro MB, 70:25
 Scheithauer BW, 67:21
 Schlegelberger B, 68:91
 Schlumberger M, 67:117
 Schmalenberger B, 66:93
 Schmidt H, 71:139
 Schraffordt Koops H, 70:12
 Schroder HD, 69:118
 Schroeter D, 67:126
 Schroyens W, 68:131
 Schwab M, 65:111
 Schwartz HS, 66:108;
 71:132
 Schwartz S, 70:127
 Schwarz M, 69:126
 Sciort R, 68:85; 71:170
 Sciotto CG, 67:136
 Secker-Walker LM, 69:129;
 70:148
 Seguchi S, 70:17
 Selleri C, 69:136
 Sen P, 66:23
 Seong D, 65:93
 Seong DC, 65:100
 Seruca R, 68:42
 Sessarego M, 67:50
 Sethuraman S, 65:12
 Seyger M, 70:112
 Shah NK, 65:135
 Shen M-C, 71:87
 Sherwin RN, 65:21
 Shi G, 70:140
 Shido T, 71:71
 Shikano T, 71:22
 Shiloh Y, 65:111
 Shimodaira S, 68:95
 Shing MK, 69:163
 Shiraishi Y, 68:70; 69:49
 Shridhar V, 71:15
 Sica S, 65:115
 Siciliano J, 65:93; 65:100

- Siciliano MJ, 65:93;
 65:100
 Siegfried JM, 69:1
 Sigut D, 66:120
 Silva MLM, 71:173
 Simoni G, 68:149
 Singh S, 70:136
 Sinke RJ, 70:85; 71:164
 Skaug V, 70:94
 Skjaeris J, 65:79
 Sledge G Jr, 68:114
 Sleijfer D T, 70:12
 Smeets W, 70:56; 71:97
 Smith D, 71:15
 Smith MR, 70:62
 Smith SE, 71:15
 Soares J, 67:1; 69:31
 Soares P, 67:1; 68:42;
 69:31
 Sobrinho-Simoes M, 68:42
 Sole F, 65:170; 69:165;
 70:152
 Sonnenberg A, 69:100
 Sonoyama M, 68:95
 Spanedda R, 71:119
 Speicher MR, 70:99
 Sperandio-Roxo VMM,
 68:82
 Spina MP, 68:140
 Spurbeck JL, 71:7
 Squadrito G, 66:113
 Sreekantaiah C, 69:17
 Staats B, 69:68
 Stalboerger P, 71:76
 Stalboerger PG, 67:21
 Standen GR, 69:22
 Stanley WS, 67:95
 Stary J, 71:67
 Stasi R, 67:28
 Steegman JL, 69:74
 Stefanescu DT, 70:71
 Steinbok P, 71:40
 Stenke L, 70:79
 Stephens KE, 65:130
 Steudel W-I, 71:151
 Stewart BW, 66:54
 Stone DM, 65:130
 Stone JF, 66:73; 70:103
 Storto PD, 65:21
 Stowasser M, 68:78
 Strehl S, 71:94
 Stul M, 69:60
 Stuppia L, 65:88
 Su I-J, 69:25
 Suciu S, 70:1
 Suenaga M, 71:71
 Sugimoto K, 69:113
 Suijkerbuijk R, 70:108
 Suijkerbuijk RF, 66:133;
 70:85; 71:164
 Sunde L, 66:16
 Sunguroglu A, 69:38
 Surti U, 67:59; 67:79;
 69:132; 71:1
 Swaney WP, 65:152
 Szymanska J, 65:141; 68:1

 T
 Tada M, 66:135
 Taguchi T, 69:1
 Taillandier J, 67:101
 Taine L, 67:7
 Tajara EH, 69:141
 Takaku F, 69:113
 Takatsu H, 71:176
 Takatsuki H, 66:103
 Talpos GB, 67:44
 Tanaka K, 70:39
 Tanindi S, 69:38
 Taniwaki M, 70:99
 Taplett J, 67:150
 Taquia E, 65:64
 Tarkkanen M, 65:141; 68:1
 Tarone RE, 70:25
 Tayyeb Tayyeb M, 67:145
 Tchernia G, 66:70
 te Meerman GJ, 70:12
 Tedeschi B, 67:28
 ten Kate J, 67:35
 Tenaglia R, 70:151
 Testa JR, 69:1
 Testoni N, 67:55
 Thibodeau SN, 71:7
 Thode B, 65:27
 Thomas G, 69:161
 Thom JA, 69:141
 Thompson CB, 68:34
 Thompson FH, 70:48
 Thompson P, 69:22
 Thompson PW, 69:41;
 71:148
 Thonnes M, 71:151
 Tiede AL, 71:7
 Tien H-F, 69:25; 71:87
 Tobon H, 67:79
 Todd I, 71:105
 Tokutake AS, 68:82
 Tomimaga R, 71:71
 Tonato M, 67:113
 Torfi H, 69:153
 Torlontano G, 65:88
 Totzeck B, 65:83
 Toyama K, 67:71; 68:143
 Toyoshima H, 69:113
 Travagli JP, 67:117
 Trent JM, 66:47; 66:137;
 70:48
 Trevor KT, 67:44
 Tribalto M, 67:28
 Tricker K, 67:133
 Trujillo JM, 65:100
 Tsai T-F, 69:25
 Tsoi WC, 69:163
 Tsuchiya H, 70:17
 Tsukamoto A, 71:71
 Tugizov SM, 65:147
 Tumewu P, 70:142
 Tunny TJ, 68:78
 Tura S, 67:55
 Turc-Carel C, 66:133
 Turker A, 69:38
 Tursz T, 66:11

 U
 Umemura T, 65:107,
 66:103
 Unal E, 69:38

 V
 Valdes E, 68:32
 Valente AN, 71:173
 Vamos E, 68:74
 Van Damme B, 68:85,
 71:170
 Van de Klundert W, 66:133
 Van de Ven W, 68:85
 Van Dekken H, 66:131
 Van Den Bergh H, 65:104;
 68:32; 68:85; 69:60;
 71:170
 van der Keur D, 65:7
 van der Plas DC, 65:7
 van Echten J, 70:85
 van Echten-Arends J,
 70:12
 Van Gaal J, 66:133
 Van Haelst A, 66:133
 van Kessel AG, 70:85;
 71:164
 VandeBerg JL, 71:55
 Vanni R, 68:32
 Vaquero J, 66:1; 66:117
 Vejerslev LO, 66:16
 Venditti A, 67:28
 Venti G, 67:113
 Venuat AM, 67:117
 Verbeek W, 70:120
 Verna T, 70:151
 Vernole P, 67:28
 Vig BK, 67:126; 70:31
 Vigui F, 69:156
 Villegas A, 70:153
 Vincent P, 70:136
 Vine AK, 66:47
 Vineis P, 68:135
 Von Hoff DD, 65:120;
 71:125
 Vyguinnyi S, 68:52

 W
 Wallace SA, 67:133
 Walsh JT, 65:120;
 71:125
 Walter TA, 71:180
 Wan TSK, 66:79; 69:163;
 70:155
 Wang C-H, 71:87
 Wang M, 65:157
 Warburton D, 65:100
 Wass J, 70:136
 Weber-Matthiesin K, 68:91
 Weh HJ, 68:49; 70:1;
 70:140
 Wei D, 65:74
 Wei DCC, 70:155
 Welborn J, 67:150
 Wellborn JL, 65:125
 Werner M, 66:130
 Wessels JW, 65:7
 Whittaker JA, 69:41;
 71:148
 Wiegant J, 71:67
 Wieland I, 65:83
 Wiener E, 65:152
 Wiersema-Buist J, 70:12
 Wilbrink M, 71:164
 Willem P, 66:75
 Wiltshire RN, 66:47
 Wingard JR, 65:135
 Winkel EW, 69:57
 Winkemann M, 68:91
 Wobst G, 65:27
 Woessner S, 65:170;
 69:165; 70:152
 Wolf J, 67:90
 Wolman SR, 67:44; 69:7
 Wood M, 69:129
 Woodhouse B, 67:108
 Wrba F, 71:94
 Wright F, 69:129
 Wullich B, 69:126;
 71:151

 X
 Xiao H, 67:141
 Xiao S, 69:91
 Xue Y, 65:157; 69:51

 Y
 Yabu U, 71:155
 Yamada S, 71:155
 Yamaguchi A, 71:176
 Yan Y-S, 69:91
 Yarkoni S, 65:32
 Yavuz G, 69:38
 Yazaki Y, 69:113
 Yehuda O, 70:117
 Yoshizawa K, 71:155

Young G, 70:136
Yu F, 65:157
Yu M-T, 65:100
Yuen PMP, 69:163

Z
Zaccaria A, 67:55
Zalupski MM, 69:35
Zang KD, 69:126; 71:151

Zeller W, 70:1
Zhang R, 69:51
Zhao Y, 65:93; 65:100
Zhou J-y, 69:1

Zhou Z, 65:157
Zinsmeister AR, 71:7
Zittoun R, 69:156
Zollino M, 65:115

Subject Index to CGC Volumes 65-71

Acrocentric Chromosomes

- increased association during colcemid, 68:52
- in human cell line, 68:52

Acute Erythroleukemia (M6)

- CD34-positive, 71:119
- chromosome changes, 71:119
- del(9q) in, 66:79
- inv(8) in, 66:77
- juvenile CML transforming to, 71:67
- pericentric inv(8) in, 66:77

Acute Lymphoblastic Leukemia (ALL)

- abnormal DNA fragments, 68:34
- bcr/abl* cosmid probe for Ph, 70:103
- bcr/abl* probe, 71:7
- chromosome changes in BMT cases, 65:135
- cytogenetics of, 67:137; 68:60; 69:122, 129
- del(6q) more common in men, 70:6
- der(14) in L3, 71:178
- Down syndrome and ALL, 70:148
- Down syndrome mosaicism and ALL, 66:70
- duplication of der(14) in L3, 71:178
- early B-precursor ALL, 69:163
- FISH studies in, 71:7
- flow cytometry and cytogenetic analysis, 67:136
- hyperdiploidy in fixed cells, 67:137; 70:6
- infantile, 69:153
- molecular studies in, 69:122
- Ph in ALL, 70:103, 153; 71:7
- T-ALL, 69:122
- t(1;19) more common in women, 70:6
- t(2;9)(p12;p23) in early pre-B ALL, 69:163
- t(4;11)(q21;p14-15) in T-ALL, 69:122
- t(4;11;13)(q21;q23;q12-14) in, 69:153
- t(6;11)(q26-27;q23) in T-ALL, 65:125
- t(8;14) more common in children with L3, 70:6
- t(8;14)(q11;q32) in, 67:55
- t(8;14)(q11;q32) in Down syndrome and ALL, 70:148
- t(8;14)(q24;q32) in L3, 71:178
- t(9;22) more common in adults with L1 + L2, 70:6
- t(14;18)(q32;q21) in L2, 65:177
- with biphenotypic features, 69:129
- +4 in L2, 65:115
- +4 in T-ALL, 69:139
- +4,+17 and Ph, 65:115
- 20 in adult ALL, 69:165
- +21 (constitutional) and ALL, 66:70; 70:148

Acute Megakaryocytic Leukemia; see Acute

Megakaryocytic

Leukemia (M7)

Acute Megakaryocytic Leukemia (M7)

- childhood MDS progression to M7, 70:17
- chromosome changes in, 65:51; 67:81; 70:17; 71:119

derivative 11 in, 66:75

- fragile sites in, 65:51
- one disease or several?, 67:81
- t(1;22)(p13;q13) in, 67:81
- t(7;11)(q11;q24) in child, 66:75
- t(12;22)(p13;q13), 65:81
- 3q21q26-7 involvement, 67:81

Acute Monocytic Leukemia (M5)

- abnormal DNA fragments, 68:35
- CD34-positive, 71:119
- chromosome changes in, 65:51; 66:126; 70:1, 6; 71:119, 173
- del(2)(p23) in M5a, 66:126
- der(11q) more common in children, 70:6
- FISH and marker chromosomes, 70:99
- fragile sites in, 65:51
- immunophenotype, 70:1
- infiltration of skin, 71:50
- multilineage involvement, 70:1
- secondary M5a, 66:126
- tetrasomy 8, 69:126
- tetrasomy 8 in M5a, 71:50
- translocation of CD3D gene, 71:173
- t(6;11)(q26-27;q23) in, 65:125
- t(9;11;14) in M5a, 71:176
- t(11;17)(q23;q21) in, 71:173
- 9p and 11q as critical regions, 71:176
- 16, 1p- and 21q+ and FISH, 70:99

Acute Myeloblastic Leukemia (M1)

- C-anaphase in, 71:148
- CD34-positive, 71:119
- chromosome changes in, 65:51; 70:1; 71:119
- FISH in, 66:73
- fragile sites in, 65:51
- immunophenotype, 70:1
- multilineage involvement, 70:1
- +4 in, 68:82
- t(16;21)(p11;q22) in, 70:144

Acute Myeloblastic Leukemia (M2)

- CD34-positive, 71:119
- chromosome changes in, 65:51; 66:39; 70:1, 6, 146; 71:119
- FISH in, 66:73
- fragile sites in, 65:51
- immunophenotype, 70:1
- MAKA and remission, 71:119
- multilineage involvement, 70:1
- t(2;4)(p23;q25) in M2, 70:140
- t(7;11)(p15;p15) with low LAP, 68:143
- t(8;21) more common in children, 70:6
- t(Y;1) in MDS evolving to M2, 70:136
- Y in t(8;21) and age, 70:6

- 5q- preceding M2, 70:146
 +14 in, 66:39
 22q- without *bcr* rearrangement, 67:141
 Acute Myeloid Leukemia (AML); see Acute
 Nonlymphocytic
 Leukemia (ANLL)
 chemical exposure, histology and cytogenetics, 68:135
 chromosome changes, 70:1
 expressing lymphoid antigens, 71:100
 FISH analysis, 67:95; 70:103
 immunophenotype, 70:1
 in Fanconi anemia, 65:47
 ins(3;4) in, 71:102
 inv(14)(q11q32) in, 71:100
 multilineage involvement, 70:1
 Ph with FISH, 70:103
 soft tissue tumors in, 71:71
 t(7;11)(p15;p15) with low LAP, 68:143
 +4 in M2, 71:71
 22q- without *bcr* rearrangement, 67:141
 Acute Myelomonocytic Leukemia (M4)
 CD34-positive, 71:119
 chromosome changes in, 65:51; 69:156, 158; 70:1, 6;
 71:119
 der(16q) more common in adults, 70:6
 fragile sites in, 65:51
 granulocytic sarcoma and Ph, 69:38
 immunophenotype, 70:1
 in XYY male, 69:156
 MAKA and remission, 71:119
 multilineage involvement, 70:1
 t(3;11)(q26;q13) in, 69:158
 t(15;17)(q24;q21) in, 70:79
 +4 in, 65:115; 68:147
 +4 in Kuwaiti case, 68:147
 +4 in M4, 70:152
 -7 more common in children, 70:6
 Acute Nonlymphocytic Leukemia (ANLL)
 C-anaphase in, 71:148
 CD34-positive, 71:119
 chemical exposure, histologic type and cytogenetics,
 68:135
 chromosome changes in, 65:51, 118; 67:28, 81; 68:60;
 70:1; 71:119
 chromosome changes in BMT cases, 65:135
 clinical correlations, 71:119
 clinical significance of cytogenetics, 67:28
 cytogenetics of M7, 67:81
 de novo ANLL, 67:28
 FISH and marker chromosomes, 70:99
 FISH and morphology, 67:95
 fragile sites in, 65:51
 immunophenotype, 70:1
 jumping translocations of 1q, 71:22
 MAKA and remission, 71:119
 MRD, PCR and BMT, 65:88
 multilineage involvement, 70:1
 NN, AN and AA classification, 67:28
 tetrasomy 8 in M5, 69:126
 t(7;11)(p15;p15) with low LAP, 68:143
 +4 and dmin in ANLL, 69:41
 Acute Promyelocytic Leukemia (APL)
 complex translocation, 69:113
 molecular studies in, 69:113
 PML/RAR α fusion gene, 69:113
 t(15;17;18) in, 69:113
 Adenomas
 pituitary, 68:140
 pleomorphic of salivary gland, 65:27
 prostatic, 66:165
 of colon, 67:7
 Adrenocortical tumors
 aldosterone producing tumor, 68:78
 benign and malignant, 66:165; 68:78
 chromosome changes, 66:165; 68:78
 Age and gender and chromosome changes
 leukemias, 70:6
 primary changes, 70:6
 secondary changes, 70:6
 Agnogenic Myeloid Metaplasia (AMM)
 t(8;12) in, 71:183
 +8 in, 71:183
 Alzheimer disease
 cancer proneness, 70:25
 DNA repair, 70:25
 X-ray induced chromatid damage, 70:25
 Anaphase
 C-anaphase in M1, 71:148
 Animals
 cytogenetic changes in nevi of opossum, 71:55
 opossum cell line, 71:55
 Astrocytoma
 allelic imbalance, 66:154
 chromosome loss, 66:145
 chromosome 6, 66:154; 71:40
 chromosome 10, 66:145
 cytogenetics of, 71:40
 pediatric, 71:40
 Ataxia Telangiectasia (AT)
 lack of p53 mutations, 66:128
 molecular studies in, 66:128
 B-cell Chronic Lymphoproliferative Disorders
 chromosome changes, 65:170
 del(7)(q32) in, 65:170
 hairy cell leukemia, 65:170
 lipopolysaccharide and B-cell growth factor for culture,
 66:135
 NHL (leukemic phase), 65:170
 splenic B-cell lymphoma, 65:170
bcr; see CML and Ph chromosome
 Biphenotypic leukemia
 chromosome changes in, 69:129
 pre-B/AML, 69:129
 Bladder cancer
 analysis of urine, washings and tumor, 71:105
 cell line, 67:101
 cytogenetic changes, 66:159; 67:101; 70:56; 71:97

- del(9)(q11q21.2) in cancer, 69:76
FISH analysis, 67:101; 70:56; 71:97, 105
karyotype and FISH analysis, 71:97; 105
heterogeneity, 70:56
monosomy 9 in, 71:97
oncogenes and suppressor genes, 66:153
- Blast crisis in CML**
clinical and biologic features, 71:87
double t(1;7)(p36;p11) in, 65:107
isodicentric Ph in accelerated phase, 66:113
lymphoid, 66:103
megakaryocytic crisis, 65:107
myeloid vs. lymphoid crisis, 71:87
variant Ph in, 65:107; 68:131
14q+ in lymphoid crisis, 66:103
- Bloom syndrome**
B-lymphoblastoid cell lines, 68:70
cell hybridization, 69:45
p53 mutation, 68:70
SCE levels in cells, 69:45
transformed cell lines, 68:70
- Bone and soft tissue tumors**
benign tumors, 68:1
bone tumors, 68:1
consecutive study of 249 cases, 68:1
cytogenetic changes, 66:148; 68:1
FISH studies in bone tumors, 68:1
telomeric association, 68:1
- Bone Marrow Transplantation (BMT)**
BMT and MRD, 65:88
chromosome changes in, 65:135
detection of MRD, 65:88
in hematologic disorders, 65:88, 135
PCR in hematologic disorders, 65:88
purged autologous marrow, 65:135
- Brain tumors**
chromosome 22 abnormalities, 66:1; 69:35
LOH in, 66:1
molecular studies, 66:1
osteosarcoma, secondary, 69:35
- Breast tumors**
benign epithelial tumors, 69:68
chromosome changes in, 65:64; 66:153, 163, 164;
69:68, 91
chromosome 13 in murine tumorigenesis, 69:100
chromosomes 1, 3 and 6 in, 69:91
comparative genomic hybridization, 66:142
cytogenetic changes in ductal cases, 66:163;
69:91
ductal, 66:163, 164; 69:91
fragile sites in breast cancer patients, 67:113, 147
fragile sites in familial, 67:108
gene in, 66:143
gene in murine tumors, 69:100
murine tumors, 69:100
polyclonal origin in patient with sarcoma, 66:153
+8 in, 65:64
+8 in ductal cancer, 66:164
12q13-15 in benign tumors, 69:68
- Burkitt lymphoma**
cell line, 67:90
E-B virus integration, 67:90
jumping translocations of 1q, 71:22
t(11;19) in, 67:90
- Cancer**
breast, 65:64
kidney, 65:1
marker BCEL, 66:168
meiotic origin of trisomic tumors, 70:112
nasopharyngeal, 66:11
oncogenes and chromosomes, 70:81
ovarian, 65:35
prostate, 66:93
- Carcinoids**
bronchial, 66:33
cytogenetic studies, 66:33
- Cartilaginous tumors**
benign tumors, 69:79
biologic and clinical significance of
chromosome changes, 69:79
chondroblastoma, 69:79
chondroma, 69:79
chondrosarcoma, 69:79
cytogenetic changes, 69:79
enchondroma, 69:79
malignant tumors, 69:79
molecular studies, 69:79
osteochondroma, 69:79
- C-banding**
chromosomes 1, 9 and 16, 65:35
heterochromatin in ovarian cancer patients, 65:35
- Cell lines**
B-cell, 70:62
bladder cancer, 67:101
Burkitt lymphoma, 67:90
cell differentiation in, 65:147
cervical cancer, 66:164
cytogenetic aneuploidy in nevi, 71:55
cytogenetic stability of squamous cell
cancer line, 66:154; 70:48, 62
cytogenetic studies in, 65:147, 161; 66:54
E-B virus associated lymphoma, 71:155
from UV-induced melanocytic nevi, 71:55
hepatocarcinoma line (PLC-PRF-5), 65:147
karyotypes in T-cell line, 66:54
liver cancer, 65:161
loss of tumorigenicity, 70:48
lymphoma, 70:62; 71:155
lymphoma from liver transplant patient, 71:155
melanoma, 69:108
methotrexate-resistant leukemia, 70:48
molecular studies in colorectal line, 66:154
opossum nevi, 71:55
ploidy in T-leukemia cell line, 66:54
SW480 (transfected) and c-Ha-ras, 67:35
T-leukemia, 66:54
telomeric sequences in HL-60 cell line, 70:132
thyroid carcinoma, 67:117

- t(2;3)(p11;q27) in liver transplant patient, 71:155
- Central Nervous System (CNS)
- chromosomes 6, 1 and 11 in, 71:40
 - CNS tumors, 71:40
 - cytogenetics of tumors, 71:40
 - pediatric tumors, 71:40
- Centromere
- in mouse, 70:31
 - separation, 70:31
 - structure and function, 66:143
- Cervical carcinoma
- cell lines, 66:164
 - chromosome changes, 66:164
- Chondroblastoma
- biologic and clinical significance of chromosome changes, 69:79
 - cytogenetic studies, 68:1; 69:79
 - FISH studies, 68:1; 69:79
 - molecular studies, 69:79
- Chondrosarcoma
- biologic and clinical significance of chromosome changes, 69:79
 - cytogenetic and molecular studies, 66:150; 68:1; 69:79; 71:144
 - FISH studies, 68:1; 69:79
 - in child, 71:144
 - mesenchymal, 71:144
 - t(11;22)(q24;q12) in, 71:144
- Chordoma
- biologic and clinical significance of chromosome changes, 69:79
 - cytogenetic changes, 69:79
 - FISH studies, 69:79
 - molecular studies, 69:79
- Choriocarcinoma
- cytogenetic changes, 68:149
 - direct chromosome analysis, 68:149
- Chromosome(s)
- acrocentric association, 68:52
 - chromosome 5 and tumorigenesis, 68:22
 - chromosome 22 c-DNA, 66:168
 - dicentric, 67:126
 - in ovarian cancer, 71:76
 - instability and SV40 antigen, 66:153
 - microdissection in tumors, 66:143, 149
 - radiosensitivity at telomeres, 66:144
 - telomere capture, 66:155
 - 1 in hepatocellular cancer, 66:130
 - 1 in renal cancer, 65:1
 - 1 in Sertoli cell tumor, 65:79
 - 1, 3 and 6 in breast cancer, 69:91
 - 3, 6 and 8 in uveal melanoma, 66:47
 - 5 and 7 in Fanconi anemia, 65:47
 - 6, 1 and 11 in brain tumors, 71:40
 - 6q and cell immortalization, 66:152
 - 7 and 10 in prostate cancer, 66:93
 - 8 in breast cancer, 65:64
 - 9 in squamous cell cancer of epiglottis, 66:23
 - 10 in astrocytoma, 66:145
 - 12 in colorectal cancer, 69:161
 - 12 in germ cell tumors, 68:114
 - 22 in brain tumors, 66:1
 - 22 in meningioma, 66:117
 - 22 in neurofibrosarcoma, 66:28
- Chromosome changes
- chromosome aberration vs. age and gender, 70:6
 - in ALL, 68:60
 - in ANLL, 65:51; 67:28; 68:60; 71:119
 - in B-cell chronic disorders, 65:170
 - in BMT patients, 65:135
 - in bone tumors, 68:1
 - in brain tumors, 71:40
 - in breast cancer, 65:64; 69:91
 - in carcinoids, 66:33
 - in cartilaginous tumors, 69:79
 - in CLL, 65:157; 68:60
 - in CML, 65:7
 - in CMMoL, 65:7
 - in colonic polyps, 67:7
 - in ependymoma, 69:146; 71:40
 - in esophageal cancer, 70:127
 - in ET, 65:51
 - in Fanconi anemia, 65:47
 - in intestinal polyps, 67:14
 - in leiomyoma, 69:132
 - in leiomyosarcoma, 65:21
 - in LPD, 68:60
 - in lymphomas, 68:60; 69:25
 - in MDS, 65:12, 51; 67:71; 68:60, 95
 - in meningioma, 66:117
 - in Merkel cell carcinoma, 67:65
 - in MPD, 68:60
 - in nasopharyngeal cancer, 66:11
 - in ovarian cancer, 65:35
 - in prostate cancer, 66:93
 - in PV, 65:51
 - in renal cancer, 65:1
 - in salivary gland adenomas, 65:27
 - in testicular tumors, 65:58
 - in thyroid adenomas, 67:1
 - in tumors, 68:60
 - in uveal melanoma, 66:47
 - repetitive changes in rat skin tumors, 66:152
 - 3q+ detected with painting, 71:67
 - 7 in leiomyoma, 67:59
- Chromosome painting
- chromosome 6, 66:157
 - in MDS, 65:175
 - of insulinoma in MEN 1, 70:68
 - of t(1;9;22), 65:100
 - probes, 65:93
 - tetrasomy 8, 65:175
 - 3qt detected with painting 71:67
- Chronic Lymphocytic Leukemia (CLL)
- cytogenetics of CLL, 70:21
 - FISH analysis of individual cells, 68:104; 70:21
 - FISH in, 66:73; 70:21
 - karyotypic changes, 65:157; 66:135; 68:60; 70:21

- lack of 5' BCL2 rearrangements, 69:72
 lipopolysaccharide and B-cell growth factor in culture, 66:135
 mitogens, 66:135
 t(8;22)(q24;q11) in, 65:157
 +12 in, 66:73; 70:21
- Chronic Myelocytic (Myeloid) Leukemia (CML)**
 accelerated phase, 66:113; 70:103
bcr/abl probe detection of Ph, 70:103, 153
bcr breakpoint and chronic phase, 70:39
 blast crisis, 65:107; 66:103, 113; 68:122, 131
 BMT and remission, 68:122
 chemical exposure, histology and cytogenetics, 68:135
 chromosome changes in, 65:7, 107; 66:103; 67:50; 68:104, 122; 70:6, 103
 clinical and biologic features of blast phase, 71:87
 detection of BCR-ABL fusion, 65:32; 70:103
 double t(1;7)(p36;p11) in crisis, 65:107
 duration of chronic phase and *bcr* breakpoint, 70:39
 FISH analysis of individual cells, 68:104
 FISH and t(1;9;22), 65:100
 FISH studies of Ph, 70:103, 153
 isodicentric Ph, 66:113
 juvenile CML, 71:67
 megakaryocytic crisis, 65:107
 molecular studies in, 66:103; 67:50; 70:39
 MRD, PCR and BMT, 65:88
 remission in case with t(3;21), 68:122
 study of two Ph's, 70:153
 t(5;12)(q31;p12) in, 65:7
 variant Ph, 65:107; 67:50; 68:131; 70:103
 3q+ in juvenile CML, 71:67
 14q+ in lymphoid crisis, 66:103
- Chronic Myelomonocytic Leukemia (CMML)**
 chromosome changes in, 65:7; 67:71
 clinical and cytogenetic correlations, 67:71
 +Ph more common in men, 70:6
 t(5;12)(q31;p12) in, 65:7
- Clear cell sarcoma**
 of kidney, 66:152
 t(4;13)(p14;q32) in tumor of kidney, 66:152
 t(12;12)(q13;q12) in CCS of tendons and aponeuroses, 66:165
- Colon**
 adenomas, 67:7, 14
 chromosomes in polyps, 67:7, 14, 123
 polyps, 67:7, 14
 7q- in colon cancer, 67:123
- Colorectal cancer**
 chromosome changes, 66:166
 chromosome 12 and c-Ki-ras, 69:161
 cytogenetic and molecular studies in cell line, 66:154; 69:161
 FISH analysis, 66:166
 mutations in, 69:161
- Comparative Genomic Hybridization (CGH)**
 amplification and deletions in ovarian cancer, 66:157
 analysis of tumors, 66:141
 global DNA sequence copy number, 66:141
 in breast cancer, 66:142
- Cytogenetic changes**
 in ALL, 68:60
 in ANLL, 65:51; 67:28; 68:60; 71:119
 in B-cell chronic disorders, 65:170
 in BMT patients, 65:135
 in bone tumors, 68:1
 in brain tumors, 71:40
 in breast cancer, 65:64; 69:91
 in carcinoids, 66:33
 in cartilaginous tumors, 69:79
 in CLL, 65:157; 68:60
 in CML, 65:7
 in CMML, 65:7
 in colonic polyps, 67:7
 in ependymoma, 69:146; 71:40
 in esophageal cancer, 70:127
 in ET, 65:51
 in Fanconi anemia, 65:47
 in intestinal polyps, 67:14
 in leiomyoma, 69:132
 in leiomyosarcoma, 65:21
 in LPD, 68:60
 in lymphomas, 68:60; 69:25
 in MDS, 65:12, 51; 67:71; 68:60, 95
 in meningioma, 66:117
 in Merkel cell carcinoma, 67:65
 in MPD, 68:60
 in nasopharyngeal cancer, 66:11
 in ovarian cancer, 65:35; 71:76
 in prostate cancer, 66:93
 in PV, 65:51
 in renal cancer, 65:1
 in salivary gland adenomas, 65:27
 in testicular tumors, 65:58
 in thyroid adenomas, 67:1
 in tumors, 68:60
 in uveal melanoma, 66:47
- Deletions**
 del(1)(p11) in PV, 68:66
 del(1)(p32) in meningioma, 70:74
 del(1)(q32) in NHL/CLD, 68:66
 del(2)(p21) in AML, 68:67
 del(2)(p23) in AML, 68:66
 del(2)(p23) in M5a, 66:126
 del(2)(q31) in CLL, 68:67
 del(3)(p11-12p14) in PV, 68:67
 del(3)(p21-25) in CLD/NHL, 68:67
 del(3)(q21) in AML/MDS, 68:67
 del(5)(p13) in ATL, 68:67
 del(5)(q12-31q31-35) in AML, 68:67
 del(5)(q13q33) in MDS, 68:67
 del(6)(q13-24q21-27) in ALL, 68:67
 del(6)(q21) in AML, 68:67
 del(6)(q21) in CLD/NHL, 68:67
 del(7)(p12p21) in AML, 68:67
 del(7)(q11) in ALL, 68:67

- del(7)(q11-34q22-36) in AML, 68:67
 del(7)(q22) in leiomyoma, 71:1
 del(7)(q22) in MDS, 68:67
 del(7)(q32) in ALL, 68:67
 del(7)(q32) in B-cell chronic disorders, 65:170
 del(7)(q36) in CLD, 68:67
 del(8)(q22) in AML, 68:67
 del(9)(p13-22) in ALL, 68:67
 del(9)(p21) in ALL, 68:67
 del(9q) in M6, 66:79
 del(9)(q11-22q21-34) in AML, 68:67
 del(9)(q11q21.2) in bladder cancer, 69:76
 del(9)(q22) in AML, 68:67
 del(10)(q24) in CLD, 68:67
 del(11)(p11-12p14-15) in AML, 68:67
 del(11)(q14) in ALL, 68:67
 del(11)(q23) in AML, 68:67
 del(12)(p11-13) in ALL, 68:67
 del(12)(p12) in AML/MDS, 68:67
 del(12)(p13) in CLD, 68:67
 del(12)(q14q21) in MPD, 68:67
 del(13)(q11-22q14-34) in ALL, 68:67
 del(13)(q12q14) in MDS/MPD, 68:67
 del(14)(q11-24q22-32) in NHL, 68:67
 del(16)(q22) in AML-M4EO, 68:67
 del(17)(q22) in AML, 68:67
 del(20)(q11) in MDS/MPD/PV, 68:67
 del(20)(q11-13) in AML, 68:67
 del(22)(q11-13) in ALL, 68:67
 del(X)(p11) in renal adenocarcinoma, 70:77
 del(X)(q13) in MDS, 68:67
 del(X)(q24) in AML, 68:67
 homozygous in tumors, 65:83
 in ANLL, 65:51; 71:119
 in esophageal cancer, 70:127
 in ET, 65:51
 in hematologic disorders, 68:60
 in MDS, 65:51
 in PV, 65:51
 PCR application in tumors, 65:83
 telomeric sequences on deleted chromosomes, 70:132
 5q- preceding M2, 70:146
 7p- in tumors, 67:123
 7q in leiomyoma, 67:59
 7q- in tumors, 67:123
 20q- in small cell lymphoma, 70:142
 22q- without *bcr* rearrangement, 67:141
Dermatofibrosarcoma protuberans
 chromosome 17, 66:158; 67:149
 karyotype of, 66:158; 67:149
 ring chromosomes, 66:158; 67:149
Desmoplastic small round-cell tumors
 chromosome changes, 69:17
 intra-abdominal, 69:17
 t(11;22)(p13;q11.2), 69:17
Dicentric
 dic(7;9)(p13;p11) in ALL, 68:65
 dic(9;12)(p11-13;p11-12) in ALL, 68:65
 formation, 67:126
 in transformed cells, 67:126
DNA
 amplification in gastric cancer, 65:111
 breaks at active genes, 68:34
 fragments in leukemia, 68:34
 in Alzheimer disease, 70:25
 in Down syndrome, 70:25
 recovery of high molecular DNA from tumors, 65:68
 repair, 70:25
 X-ray induced damage, 70:25
 11q23 changes and DNA fragments, 68:34
Double minute chromosomes (dmin)
 absence of telomeric sequences, 70:132
 dmin and gene amplification, 65:120
 in gastric cancer, 68:42
 in giant cell tumor of bone, 66:108
 in lung cancer, 65:120
 in ovarian cancer, 71:125
 +4 and dmin in ANLL, 69:41
Down syndrome
 ALL in, 66:70; 70:148
 cancer proneness, 70:25
 DNA repair, 70:25
 early B-lineage ALL, 70:148
 t(8;14)(q11;q32) in ALL, 70:148
 X-ray induced chromatid damage, 70:25
 +21 mosaicism and ALL, 66:70
Duplications
 chromosomal, in hematologic disorders, 68:60
 dup(1)(q11q44) in MPD, 68:66
 dup(1)(q21q31) in NHL/CLD, 68:66
 dup(1)(q21q32) in MPD, 68:66
 dup(11)(q13q23-25) in NHL, 68:66
Enchondroma
 biologic and clinical significance of chromosome changes, 69:79
 cytogenetic changes, 69:79
 FISH studies, 69:79
 molecular studies, 69:79
Endodermal Sinus Tumor (EST)
 cytogenetic changes, 66:162
 in infants, 66:162
Endometrial polyp
 chromosome 12 changes, 66:159; 68:32
 12q13-15 changes, 68:32
Endometrial stromal sarcoma
 karyotypic changes, 66:159
Eosinophilia
 in MDS with t(12;21)(q32;q22), 68:95
Ependymoma
 cytogenetic changes, 66:162; 69:146; 71:40
 genesis and progression, 69:146
 major numerical changes, 69:146
 pediatric, 71:40
 structural changes, 69:151
Epstein-Barr Virus (EBV)
 cytogenetics of EBV tumors, 69:25

- EBV and T-cell malignancies, 69:25
in lymphoma from liver transplant patient, 71:155
- Esophagus
cell cultures of cancer, 70:127
cytogenetics of cancer, 70:127
squamous cell carcinoma, 70:127
- Essential Thrombocythemia (ET)
chromosome changes in, 65:51, 74
fragile sites in, 65:51
near-octaploidy in, 65:74
- Ewing sarcoma
chromosome changes, 68:1
extraosseal, 68:1
t(11;22)(q24;q12) in, 66:167; 68:1
- Familial adenomatous polyposis
pedigree and phenotype, 66:150
- Familial Atypical Multiple Mole Melanoma; see FAMMM
- FAMMM syndrome
chromosome instability in, 71:27
familial studies, 71:27
- Fanconi anemia
AML in, 65:47
chromosome breakage and cell cycle, 69:13
chromosome changes in marrow, 65:47
MRD, PCR and BMT, 65:88
- Fibrolipoma
t(12;16)(q13;q24) in, 67:145
- Fibroma
cementifying fibroma, 71:170
chondromyxoid, 65:141; 68:1, 104; 69:79
chromosome changes, 68:1; 69:79; 71:170
FISH analysis of individual cells, 68:104
ins(5;2)(q13;p21p25), 65:141
molecular studies, 69:79
2p-, 65:141
- Fibrosarcoma
chromosome changes in, 65:152
congenital, 65:152
infantile, 71:94
t(12;13) in infantile, 71:94
+11,+17,+20 in congenital, 65:152
- Fifth International Workshop on Chromosomes
in Solid Tumors
abstracts, 66:141-168
overview, 66:138
preface, 66:137
- FISH; see Fluorescence-In-Situ Hybridization
- Flow cytometry
hyperdiploidy, 67:136
in ALL, 64:136
- Fluorescence-In-Situ Hybridization (FISH)
application of metaphase and interphase chromosomes,
66:141; 70:21
chromosome 17 in dermatofibrosarcoma protuberans,
66:158; 67:149
clinical usefulness, 65:32, 100
detection of BCR-ABL fusion, 65:32; 70:103
detection of variant Ph, 65:100
DNA mapping, 66:144
in ANLL (marker chromosomes), 70:99
in bladder cancer, 67:101; 70:56; 71:105
in bone tumors, 68:1
in germ cell tumors, 68:114; 70:85
in glioblastomas, 66:168
in head and neck tumorigenesis, 66:142
in individual cells, 68:104
in neuroblastoma, 66:145
in non-small cell lung cancer, 69:1
in prostate cancer, 66:142; 69:7
in rhabdomyosarcoma, 68:99
in round cell tumors with t(11;22), 66:167
in tumors, 66:157
in various disorders, 66:73
mapping of region 22q13.1, 70:108
of pancreatic cancer, 66:147
orientation of satellite DNA sequences, 66:143
paraffin vs. metaphase analysis, 69:7
Ph in AML and ALL, 70:103
Ph in CML and ALL, 71:7
phenotype and genotype in individual cells, 68:104
ring chromosome in adipose tumors, 68:85
studies in ALL, 71:7
studies in CML, 65:32, 100; 70:103, 153
telomeric sequences, 70:132
testing of 16 probes on a single slide, 68:91
urine analysis in bladder cancer, 71:105
use in paraffin blocks, 66:157; 68:99
+7 in normal lung and kidney cells, 66:100
+12 in CLL, 70:21
- Fragile sites
aphidicolin-induced, 67:108, 113
familial breast cancer, 67:108
folate-sensitive and aphidicolin-induced in cat,
65:130
in breast cancer patients, 67:113; 147
in domestic cat, 65:130
in myeloid disorders, 65:51
in various species, 65:134
- Ganglioneuromas
cytogenetics of, 71:40
pediatric, 71:40
- Gastric cancer
cytogenetic findings, 68:42
dmin and hsr in, 68:42
DNA amplification, 65:111
molecular studies, 65:111
oncogenes, 65:111
polysomy 2 and 20, 68:42
structural changes of chromosomes 3 and 13, 68:42
- Gastrinomas
chromosome changes, 67:44
- Gene
amplification in lung cancer, 65:120
amplification in ovarian cancer, 66:155
CD3D gene and t(11;17) in M5, 71:173
dmin and gene amplification, 65:120

- GCSF and i(17q) in ANLL, 68:49
 gene on chromosome 13 in murine breast tumors, 69:100
 genomic fluidity, 66:149, 156
 lack of 5' BCL2 rearrangements in CLL, 69:72
 multidrug resistance and amplification, 66:148
 oncogenes and suppressor genes in bladder cancer, 66:153
 PML/RAR α in APL, 69:113
 p53 in ataxia-telangiectasia, 66:128
 p53 in Bloom syndrome, 68:70
 p53 in Li-Fraumeni syndrome, 66:83
 regulation of amplification, 66:148
- Germ cell tumors
 chromosome 12, 68:114
 extragonadal, 66:167
 FISH studies, 68:114
 mediastinal and MDS, 66:165
 testicular, 68:114
 trisomy 2 and 3, 66:161
 7q- in tumors of testes, 67:123
 12p sequences and i(12p) in testicular tumors, 66:167
- Giant cell tumor of bone
 chromosome changes in, 66:108; 68:1
 FISH studies, 68:1
 growth factor beta in, 66:108
 molecular studies, 66:108
 telomere reduction, 71:132
 telomeric association, dmin, rings and other changes, 66:108
- Giant congenital nevus
 chromosome changes, 68:74
 cultured melanocytes, 68:74
- Glioma
 chromosome 22 anomalies, 66:1
 cytogenetic and molecular studies, 66:154
 FISH studies, 66:168
 molecular studies, 66:1
- Gliososis
 clonal cytogenetic changes, 67:21
 cytogenetics of gliotic brain, 67:21
- Granulocytic sarcoma
 AML and granulocytic sarcoma, 69:38
 orbito-ocular involvement, 69:38
 Ph in case, 69:38
- Hairy cell leukemia (HCL)
 chromosome changes, 65:170
 del(7)(q32) in, 65:170
- Hemangiopericytoma
 chromosome changes, 66:160; 71:151
 extracranial, 71:151
 recurrent cytogenetic changes, 66:160; 71:151
 t(12;19)(q13;q13.3) in, 71:151
- Hepatocarcinoma
 cell line, 65:147, 161
 chromosome changes in cell line, 65:147, 161; 66:130
 chromosome 1, 66:130
- Hibernoma
 cytogenetic changes, 66:162
- Hodgkin disease (HD)
 chromosome changes in BMT cases, 65:135
- Homogeneously Staining Regions (hsr)
 in gastric cancer, 68:42
- Hydatidiform moles
 genetic analysis, 66:16
 molecular studies, 66:16
 repeated, biparental and diploid, 66:16
- Hypernephroma
 chromosome changes, 68:1
 bone metastasis, 68:1
- Insertions
 ins(3;3)(q26;q21q26) in AML, 68:65
 ins(3;4) in AML, 71:102
 ins(5;2)(q13;p21p25) in a chondromyxoid sarcoma, 65:141
 ins(10;11)(p11;q23q24) in AML, 68:65
- In-situ hybridization method, 70:21
 +12 in CLL, 70:21
- Interphase cytogenetics; also see FISH
 in bladder cancer, 70:56
- Inversions
 in hematologic disorders, 68:60
 inv(3)(q21q26) in MDS, 68:66
 inv(3)(q21q26) in M7, 67:81
 inv(7)(q21q31) in breast cancer, 65:64
 inv(8), pericentric in M6, 66:77
 inv(12)(p12-13q14-15) in endometrial polyp, 68:32
 inv(14)(q11q32) in AML with lymphoid antigens, 71:100
 inv(14)(q11q32) in T-CLL/T-CLD/T-NHL, 68:66
 inv(16)(p13q22) in AML-M4EO/MDS, 68:66
- Isochromosomes
 idic(X)(q13) in AML, 68:66
 in ANLL, 71:119
 in hematologic disorders, 68:60
 isodicentric Ph, 66:103
 i(1q) in Sertoli cell tumor of ovary, 65:79
 i(7q) in AML/CLD/MDS/NHL, 68:66
 i(8q) and i(17q) in gastric cancer, 68:42
 i(8q) in uveal melanoma, 66:47
 i(9p) in MDS, 68:66
 i(9q) in ALL, 68:66
 i(9q) and i(11p) in Merkel cell carcinoma, 67:65
 i(9q) in squamous cell cancer of epiglottis, 66:23
 i(11q) in AML, 68:66
 i(12p) in AML, 68:66
 i(14q) in AML/MPD, 68:6
 i(17q) and GCSF gene, 68:49
 i(17q) in AML/MDS/MPD, 68:66
 i(21q) in AML/MDS, 68:66
- Karyotypic anomalies
 in ALL, 68:60
 in ANLL, 65:51; 67:28; 68:60; 71:119
 in B-cell chronic disorders, 65:170
 in BMT patients, 65:135
 in bone tumors, 68:1

- in breast cancer, 65:64; 69:91
- in carcinoids, 66:33
- in cartilaginous tumors, 69:79
- in CLL, 65:157; 68:60
- in CML, 65:7
- in CMMoL, 65:7
- in colonic polyps, 67:7
- in ependymoma, 69:146
- in esophageal cancer, 70:127
- in ET, 65:51
- in Fanconi anemia, 65:47
- in intestinal polyps, 67:14
- in leiomyoma, 69:132
- in leiomyosarcoma, 65:21
- in LPD, 68:60
- in lymphomas, 68:60; 69:25
- in MDS, 65:12, 51; 67:71; 68:60, 95
- in meningioma, 66:117
- in Merkel cell carcinoma, 67:65
- in MPD, 68:60
- in nasopharyngeal cancer, 66:11
- in ovarian cancer, 65:35; 71:76
- in prostate cancer, 66:93
- in PV, 65:51
- in renal cancer, 65:1
- in salivary gland adenomas, 65:27
- in testicular tumors, 65:58
- in thyroid adenomas, 67:1
- in tumors, 68:60
- in uveal melanoma, 66:47
- Keratinocytes
 - chromosome 5 and tumorigenesis, 68:22
 - immortalization, 68:22
- Kidney tumors; see Renal tumors
 - +7 in normal cells, 66:100
- Lacrimal gland
 - cytogenetics of tumors, 66:163
 - tumors, 66:163
- Large granular lymphocyte leukemia
 - chromosome changes, 69:25
 - EBV, 69:25
- Leiomyoma
 - biclonality of chromosome 7, 67:59
 - chromosome 7, 67:59; 79
 - cytogenetic changes, 69:132
 - del(7)(q22) in, 71:1
 - symplastic, 67:79
 - uterine, 67:59
 - 10q22 in, 69:132
- Leiomyosarcoma
 - chromosome changes in, 65:21
 - sinonasal tract, 65:21
- Li-Fraumeni syndrome
 - complicating conditions, 66:83
 - molecular studies in, 66:83
 - p53 in, 66:83
 - sarcomas and carcinomas in, 66:83
 - Wilms tumor in, 67:133
- Lipoma
 - bone lipoma, 68:1
 - chromosome 12 breakpoint, 66:158
 - cytogenetic changes in, 68:1, 85
 - FISH studies, 68:1, 85
 - ring chromosomes and chromosome 12 sequences, 68:85
 - t(12;16)(q13;q24) in fibrolipoma, 67:145
- Liposarcoma
 - chromosome 12, 66:133, 158
 - cytogenetic changes, 68:85
 - FISH studies, 66:133, 68:85
 - myxoid, 66:158
 - origin of ring, 66:133, 68:85
 - well-differentiated, 66:133
- Liver cancer; see Hepatocarcinoma
- Loss of Heterozygosity (LOH)
 - in brain tumors, 66:1
 - in neurofibrosarcoma, 66:28
 - LOH of chromosome 1 in rat mammary tumors, 66:152
- Lung cancer
 - der(9;15)(q10;q10) in non-small cell cancer, 69:1
 - dmin and gene amplification, 65:120
 - FISH studies in cancer, 69:1
 - gene amplification, 65:120
 - molecular studies in, 65:83
 - non-small cell cancer, 69:1
 - +7 in normal cells, 66:100
 - 9q;15q translocation, 69:1
- Lymphocytes
 - "rogue" lymphocytes, 66:148
- Lymphoma
 - angiocentric, 69:25
 - cell line with t(2;3)(p11;q27) from liver transplant patient, 71:155
 - cell line with t(14;18) and t(8;11), 70:62
 - chromosomal damage, 66:156
 - chromosome changes in BMT cases, 65:135
 - c-myc in cell line, 70:62
 - cytogenetic changes, 68:60; 69:25; 70:62
 - EBV and lymphoma, 69:25; 71:155
 - EBV-negative lymphoma, 70:62
 - HRAS1 alleles outside VTR region, 69:60
 - immunoblastic, 69:25
 - molecular studies in, 69:60; 70:62
 - T-cell, 65:71; 70:71
 - t(8;11;14) in T-lymphoma, 70:71
 - t(8;13)(p11.2;q12) in T-cell, 65:71
 - 20q- in small cell lymphocytic, 70:142
- Lymphoproliferative Disorders (LPD)
 - chromosome changes, 68:60; 70:6
 - cytogenetics, age and gender, 70:6
- Malignant Rhabdoid Tumor (MRT)
 - of kidney, 66:161
- Mammary tumors; see Breast tumors
- Mapping
 - of breakpoint on chromosome 11, 69:122
 - of t(4;11)(q21;p14-15) in T-ALL, 69:122
 - 22q13.1 cosmid mapping and locus linkage, 70:108

M-BCR breakpoint; see CML and Ph chromosome

Meiosis

and trisomic neoplasms, 70:112

Melanoma

cell lines, 69:108

chromosome microdissection in, 66:149

chromosome 3 and uveal melanoma, 66:151

chromosomes 3, 6 and 8, 66:47

cytogenetic analysis, 66:47, 151, 164, 165; 69:108

cytogenetic homogeneity, 69:108

FAMMM syndrome, 71:27

uveal, posterior, 66:47, 151

+8 and i(8q), 66:47

Meningioma

chromosome 22 anomalies, 66:1, 117; 70:74

del(1)(p32) as sole anomaly, 70:74

heterozygosity of 22, 66:117

molecular studies, 66:1, 117

RFLP studies in, 66:117

Merkel cell carcinoma

chromosomes 1, 11 and 13 in, 67:65

cutaneous, primary, 66:153

cytogenetic changes, 66:153; 67:65

metastatic, 67:65

MIC2 gene in, 66:153

Mesothelioma

chromosomes 1, 14, 21 and 22, 70:94

karyotypic changes, 70:94

malignant, 70:94

Methods

field-inversion gel electrophoresis, 65:68

recovery of high-molecular weight DNA from tumors, 65:68

Minimal Residual Disease (MRD)

BMT and MRD, 65:88

in hematologic diseases, 65:88

PCR and MRD, 65:88

Molecular studies

amplification unit on 12q, 66:146

cloning of t(3;6)(p14;p11), 71:15

in ALL, 67:55

in AML (M2), 67:141

in ANLL with i(17q), 68:49

in APL, 69:113

in ataxia telangiectasia, 66:128

in Bloom syndrome, 68:70

in brain tumors, 66:1

in CML, 65:32; 107; 66:103; 67:50; 70:39

in colorectal cancer, 69:161

in gastric cancer, 65:111

in giant cell tumor of bone, 66:108

in hydatidiform moles, 66:16

in Li-Fraumeni syndrome, 66:83

in lung cancer, 65:83

in lymphoma (HRAS1), 69:60

in MDS, 65:12

in neurofibrosarcoma, 66:28

in T-ALL, 69:122

mapping of 22q13.1, 70:108

methods, 66:142, 144

myc amplification, 66:155

of abnormal DNA fragments in acute leukemia, 68:34

PCR, deletions and tumors, 65:83

PCR in, 65:83

RAS oncogene, 65:12

telomere reduction in tumor and with aging, 71:132

Monosomy

in hematologic disorders, 68:60

in MDS, 65:53

in PV, 65:54

-7 in M7, 67:81

-9 in bladder cancer, 71:97

-20 in adult ALL, 69:165

22 in PNET, 66:161

Muir-Torre syndrome

cytogenetic studies, 66:162

Multiple Endocrine Neoplasia syndrome (MEN)

chromosome analysis of insulinoma, 70:68

insulinoma in, 70:68

MEN1 and insulinoma, 70:68

Multiple Myeloma

aneuploidy in, 66:156

chromosome changes, 68:60

MRD, PCR and BMT, 65:88

secondary MDS, 70:117

t(1;1) in, 70:117

Murine tumors

chromosome 13, 69:100

gene in trisomic and pentasomic #13, 69:100

Mutations

point in MDS, 65:12

p53 in Li-Fraumeni syndrome, 66:83

Myelodysplasia; see Myelodysplastic syndromes

Myelodysplastic syndromes

cell lineage in MDS, 70:120

chemical exposure, histology and cytogenetics, 68:135

childhood MDS, 70:17

chromosome changes in, 65:12, 51, 175; 66:39; 67:71

clinical aspects and cytogenetics, 67:71

cytogenetic findings in, 65:12, 51, 175; 66:39; 67:71;

68:60, 95; 70:6, 17, 117

cytogenetics, age and gender, 70:6

del(8)(q22) and +19 in, 65:12

eosinophilia with t(12;21)(q23;q22), 68:95

FISH analysis of individual cells, 68:104

FISH in, 66:73; 70:120

immunophenotyping in MDS, 70:120

in India, 65:12

in treated multiple myeloma, 70:117

karyotype in, 65:12, 51, 175; 66:39; 67:71;

70:6, 17, 117

MDS progressing to M7, 70:17

mediastinal germ cell tumor and MDS, 66:165

MRD, PCR and BMT, 65:88

mutations in, 65:12

RAS oncogene, 65:12

SCE in, 65:12

tetrasomy 8 in, 65:175

therapy-related, 70:117

- t(1;7) and cell lineage, 70:120
t(12;14)(q13;q32) in RAEB-t, 65:76
t(Y;1) in MDS, 70:136, 155
t(Y;1) in MDS evolving to M2, 70:136
+8 and cell lineage, 70:120
+13 in MDS progressing to M1, 69:136
+14 in, 66:39
- Myeloproliferative Diseases (MPD)
chromosome changes, 68:60; 70:6
cytogenetic changes, age and gender, 70:6
- Myxoma
cardiac, 66:155
telomeric association in, 66:155
- Nasopharyngeal carcinoma
cytogenetic studies, 66:11
xenografted, 66:11
- Neoplasms; see Tumors
- Neurinoma
chromosome 22 anomalies, 66:1
molecular studies, 66:1
- Neuroblastoma
chromosome changes, 65:167
FISH for detection of genomic changes, 66:145
high incidence of constitutional translocations, 69:166
i(1q) and t(1;5)(p22;q13), 65:167
N-myc amplicon, 66:145
1p loss, 66:145
- Neurocytoma
central, 65:173
cytogenetics of, 65:173
- Neuroendocrine carcinoma; see Merkel cell carcinoma
primary cutaneous, 66:153
- Neurofibromatosis
cellular radiosensitivity, 66:120
molecular studies, 66:28
Saudi patients, 66:120
skin fibroblasts, 66:120
Type 1 and neurofibrosarcoma, 66:28
- Neurofibrosarcoma
in NF-1, 66:28
LOH in, 66:28
molecular studies in, 66:28
22q12 in, 66:28
- Non-Hodgkin lymphoma (NHL); see Lymphoma
- Nucleolar Organizer Regions (NOR)
ectopic in testicular tumors, 65:58
in testicular tumors, 65:58
- Oncogenes
and chromosomes, 70:81
BCR-ABL fusion, 65:32
c-Ha-ras in karyotypic instability, 67:35
c-Ki-ras in colorectal cancer, 69:161
ETS1 and abnormal DNA fragments in acute leukemia, 68:34
HRAS1 in lymphomas, 69:60
in bladder cancer, 66:153
in gastric cancer, 65:111
myc amplification, 66:155
N-myc in neuroblastoma, 66:145
RAS in MDS, 65:12
- Osteoblastoma
loss of 17p, 69:65
t(17;20)(p11-12;q11) in, 69:65
unbalanced translocation, 69:65
- Osteochondroma
biologic and clinical significance of chromosome changes, 69:79
cytogenetic changes, 69:79
FISH studies, 69:79
molecular studies, 69:79
- Osteosarcoma
benzpyrene induced in rat, 71:139
chromosome changes, 66:160; 68:1; 69:35; 71:139
chromosome changes in rat osteosarcoma, 71:139
chromosome 13 in, 69:35
in rat, 71:139
metastases to lung, 68:1
periosteal, 68:1
parosteal, 68:1
secondary, 69:35
- Ovarian cancer and tumors
clinical correlates, 65:35; 71:76
cytogenetic changes, 65:35; 66:161; 71:76
double minutes in, 71:125
gene amplification, 66:155, 157
germ cell tumors, 66:161
heterochromatic variants, 65:35
Sertoli cell tumor with i(1q), 65:79
teratoma, chromosome changes, 66:161
thecoma, 71:180
therapy-related cytogenetic changes, 65:35
+12 in thecoma, 71:180
- p53 gene; see Gene
- Pancreatic cancer and tumors
chromosomes in, 66:147, 166
FISH analysis, 66:147
gastrinoma, 67:44
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
MRD, PCR and BMT, 65:88
- Philadelphia (Ph) chromosome; see Ph-translocation
- Ph-translocation and chromosome
bcr/abl cosmid probe for, 70:103; 71:7
BCR-ABL fusion, 65:32, 107; 71:7
in ALL (L2), 65:115; 70:103, 153
in AML, 70:103; 71:7
in AML with granulocytic sarcoma, 69:38
in CML, 65:32, 100, 107; 66:103, 113; 67:50; 70:103, 153; 71:7
isodicentric, 66:113
Ph in thrombocytopenic purpura, 69:51
two Ph in cases of CML and ALL, 70:153
t(1;9;22) detected with FISH, 65:100
t(5;9;22) in CML, 65:107
t(11;9)(9;22)(q23;p22q34;q11), 68:131

- variant translocation, 65:100, 107; 67:50;
68:131; 70:103, 71:7
- Pineocytoma
chromosome changes, 71:185
- Pituitary
adenoma, 68:140; 69:118
chromosomes in adenoma, 68:140; 69:118
numerical changes in adenoma, 69:118
- Polycythemia Vera (PV)
chromosome changes in, 65:51; 68:60
fragile sites in, 65:51
t(8;21) prior to acute leukemia, 70:125
- Polymerase Chain Reaction (PCR)
detection of PML/RAR α fusion gene, 69:113
detection of tumor-specific deletions, 65:83
dual *alu* primers, 65:93
hematologic disorders, BMT and MRD, 65:88
in MRD, 65:88
painting probes and, 65:93
use of tumor biopsies with, 65:83
- Polyps
of colon, 67:7
of intestine, 67:14
- Primitive Neuroectodermal Tumor (PNET)
chromosome changes, 68:1
of brain, 66:161
45,XY,-22 in, 66:161
- Probes
bcr/abl cosmid probes, 70:103
chromosomes from hybrid cells, 65:93
chromosome painting probes, 65:93
locus probes in tumors, 66:141
painting and t(1;9;22), 65:100
- Prolymphocytic leukemia
chromosome changes, 66:135
lipopolysaccharide and B-cell growth factors in culture,
66:135
- Prostate
adenomas, 66:165
benign prostatic hyperplasia (BPH), 68:126; 70:151
cancer, 66:93; 68:126; 69:7
chromosome changes in BPH, 68:126; 70:151
chromosome changes in cancer, 67:123; 69:7
chromosomes in adenomas, 66:165
cytogenetic survey of cancers, 66:93
FISH: paraffin vs. metaphase analysis, 69:7
FISH studies of ploidy, 66:142
genetic heterogeneity in cancer, 66:147
-Y in prostate but not stromal cells, 66:131
-Y,+7 and del(10)(q24) in cancer, 66:93
7q- in cancer, 67:123
- Rat
benzpyrene induced osteosarcoma, 71:139
chromosome changes in osteosarcoma, 71:139
osteosarcoma in, 71:139
- Refractory anemia (RA)
chromosome changes in, 65:51; 66:39; 67:71; 69:136;
70:6
clinical and cytogenetic correlations, 67:71; 70:6
del(5q) more common in women, 70:6
fragile sites in, 65:51
MRD, PCR and BMT, 65:88
+13 in progression to M1, 69:136
+14 in, 66:39
- Refractory anemia with excess of blasts (RAEB)
chromosome changes in, 65:51; 66:39; 67:71
clinical and cytogenetic correlations, 67:71
eosinophilia with t(12;21)(q32;q22), 68:95
fragile sites in, 65:51
+14 in, 66:39
- Refractory anemia with excess of blasts in transformation
(RAEB-t)
chromosome changes in, 65:51; 67:71
clinical and cytogenetic correlations, 67:71
fragile sites in, 65:51
t(6;9)(p22.3;q34) in, 69:74
t(12;14)(q13;q32) in, 65:76
- Refractory anemia with ringed sideroblasts (RARS)
chromosome changes in, 65:51; 67:71
clinical and cytogenetic correlations, 67:71
fragile sites in, 65:51
- Renal tumors
chromosome changes, 65:1; 66:159; 71:164
chromosome 11 and mesoblastic nephroma, 66:151
clear cell sarcoma, 66:152
cytogenetic classification, 66:159
del(X)(p11) in adenocarcinoma, 70:77
papillary cancer, 65:1; 71:164
rhabdoid, 66:161
Wilms in cancer family, 67:133
t(X;1) in, 65:1; 71:164
YAC spanning the t(X;1), 71:164
Xp11.2 breakpoint, 71:164
+7 in normal cells, 66:100
- Rhabdomyosarcoma
alveolar, 66:43, 146
chromosome changes, 66:43; 68:99
FISH: detection of aneuploidy and deletions, 68:99
FISH in paraffin-embedded cells, 68:99
molecular genetic studies, 66:150
ocular, 66:43
translocations and other changes, 66:43; 68:99
t(2;13) in, 66:146
- Ring chromosomes
chromosome 12 sequences in lipoma and LPS,
68:85
in dermatofibrosarcoma protuberans, 66:158
in giant cell tumor of bone, 66:108
in hematologic disorders, 68:60
in liposarcoma, 66:133; 68:85
origin of ring, 68:85
- Salivary gland
adenomas, 65:27
correlation of chromosome changes with histology
and in vitro behavior, 65:27
cytogenetic subtypes, 65:27

- multiple genetic events in adenoma, 66:146
- pleomorphic, 65:27
- Sarcoma
 - chondrosarcoma, 68:1
 - fibrosarcoma (congenital), 65:152
 - FISH in, 68:1
 - leiomyosarcoma, 65:21
 - osteosarcoma, 68:1
- Secondary acute leukemia
 - chromosome changes, 70:1, 6
 - cytogenetics, age and gender, 70:6
 - immunophenotype, 70:1
 - multilineage involvement, 70:1
- Sertoli cell tumor
 - i(1q) in ovarian tumor, 65:79
 - of ovary, 65:79
 - Y in tumor, 65:104; 66:163
- Sister Chromatid Exchange (SCE)
 - in myelodysplasia, 65:12
 - in Waldenström macroglobulinemia, 66:63
- Small round cell tumors
 - t(11;22)(q24;q12) in, 66:167
- Soft tissue tumors
 - leiomyosarcoma, 65:21
- Squamous cell carcinoma
 - chromosome changes, 66:23; 147, 166
 - chromosome 7, 66:166
 - chromosome 9 changes in glottis cancer, 66:23
 - chromosome 18 and response to TGFB, 66:151
 - chromosomes in head and neck cancer, 66:147
 - cytogenetic stability of cell line, 66:154
 - FISH studies, 66:166
 - monoclonal origin of head and neck cancer, 66:150
 - of glottis, 66:23
 - oral, 66:166
 - 18q- and homozygosity for DCC locus, 66:146
- Stomach cancer
 - DNA amplification, 65:111
 - molecular studies, 65:111
 - oncogenes, 65:111
- Synovial sarcoma
 - breakpoint in X chromosome, 71:164
 - cytogenetic changes, 66:160
- T-cell
 - ALL, 65:125
 - angiocentric lymphoma, 69:25
 - chromosome changes in T-cell tumors, 69:25
 - EBV and T-cell tumors, 69:25
 - immunoblastic lymphoma, 69:25
 - lymphoma, 65:71; 69:25
 - T-leukemia cell line, 66:54
 - t(6;11) in T-ALL, 65:125
- Telomere(s)
 - absence of sequences on dmin, 70:132
 - reduction in giant cell tumor of bone, 71:132
 - reduction with aging, 71:132
 - sequences on deleted chromosomes, 70:132
- Telomeric association (tas)
 - in bone tumors, 68:1
 - in cardiac myxoma, 66:155
 - in giant cell tumor of bone, 66:108; 68:1
 - in Wilms tumor, 69:141
- Teratoma
 - ovarian, 66:161
- Testicular tumors
 - cell line of germ cell tumor, 68:114
 - chromosome anomalies, 65:58; 67:123; 68:114, 70:12
 - chromosome 12 in germ cell tumors, 68:114; 70:85
 - cytogenetics and clinical stage, 70:12
 - cytogenetics of nonseminomatous tumors, 70:12
 - ectopic NOR in, 65:58
 - FISH studies, 68:114; 70:85
 - germ cell tumors, 68:114; 70:12, 85
 - i(12p)-negative germ-cell tumors, 70:85
 - Sertoli tumor, 65:104
 - Y in Sertoli tumor, 65:104
 - 7q- in, 67:123
 - 12p and i(12p) in germ cell tumors, 66:167; 70:12, 85
 - 12p sequences: overrepresentation, 70:85
- Tetrasomy
 - chromosome 13 in murine breast tumor, 69:100
 - tetrasomy 8 in ANLL, 69:126; 71:50
 - tetrasomy 8 in MDS, 65:175
 - tetrasomy 8 in M5a, 71:50
- Thecoma
 - ovarian, 71:180
 - +12 in ovarian thecoma, 71:180
- Thrombocytopenic purpura
 - amegakaryocytic, 69:51
 - Ph+, 69:51
- Thyroid tumors and conditions
 - adenomas, follicular, 67:1
 - carcinoma, papillary, 67:117
 - cell line, 67:117
 - chromosomes in nodular hyperplasia, 69:31
 - cytogenetics changes in cancer, 67:117
 - cytogenetics of adenoma, 67:1
 - nodular hyperplasia, 69:31
- Translocations
 - constitutional in neuroblastoma, 69:166
 - in hematologic disorders, 68:60
 - in leiomyosarcoma, 65:21
 - jumping translocations of 1q, 71:22
 - translocations in malignant diseases, 66:141
 - t(X;1)(p11;q21) in papillary renal cell tumor, 71:164
 - t(X;1)(p11.2;q21) in renal cancer, 65:1
 - t(X;11)(q13;q23) in AML, 68:66
 - t(X;11)(q24-25;q23) in AML, 68:66
 - t(X;14)(p11.4;q11) in immunoblastic lymphoma, 69:25
 - t(Y;1)(q12;q21) in MDS, 68:66; 70:155
 - t(Y;1)(q12;q21) in M2 after MDS, 70:136
 - t(1;1) in myeloma, 70:117
 - t(1;2)(p22;q23) in germ cell tumor, 68:114
 - t(1;2)(q34;q11) in breast cancer, 69:91
 - t(1;3)(p31;q11) in LPS, 68:85
 - t(1;3)(p36;q21) in AML/MDS, 68:65
 - t(1;3)(q42;q21) in meningioma, 66:118

- t(1;4)(p13;q31) in leiomyoma, 67:59
 t(1;4)(p31;p16) in nasopharyngeal cancer, 66:12
 t(1;4)(q23;q31) in large granular lymphocyte leukemia, 69:25
 t(1;5)(p13;q31) in gastric cancer, 68:42
 t(1;5)(p22;q13) in neuroblastoma, 65:167
 t(1;5)(p36;p13) in Merkel cell carcinoma, 67:65
 t(1;5)(q21;q32) in thyroid adenoma, 67:1
 t(1;5)(q21;q35) in alveolar rhabdomyosarcoma, 66:43
 t(1;6)(p22;q23) in germ cell tumor, 68:114
 t(1;6)(q21;q12) in nasopharyngeal cancer, 66:12
 t(1;7) in MDS, 70:120
 t(1;7)(p11;p11) in AML/MDS, 67:71; 68:65
 t(1;7)(p36;p11) in crisis of CML, 65:107
 t(1;8)(p10;q10) in breast cancer, 69:91
 t(1;8)(p11;p11) in thyroid cancer, 67:117
 t(1;9)(p11;p11) in PV, 68:65
 t(1;9)(p11;p12) in thyroid cancer, 67:117
 t(1;9)(q43;p11) in thyroid cancer, 67:117
 t(1;9;22)(q22;q34;q11) variant Ph in CML, 67:50
 t(1;11)(p10;q10) in breast cancer, 69:91
 t(1;11)(p32;q23) in ALL, 68:65
 t(1;11)(q21;q23) in AML-M4,M5, 68:65
 t(1;14)(p13;q31) in breast cancer, 69:91
 t(1;14)(p32-34;q11) in T-ALL, 68:65
 t(1;15)(p32;q21) in chondrosarcoma, 69:79
 t(1;15)(q21;q24) in gastric cancer, 68:42
 t(1;16)(q44;p11.2) in pituitary adenoma, 68:140
 t(1;17) in sAML, 70:1
 t(1;17)(p36;q21) in AML, 68:65
 t(1;19)(p11;p11) in sAML, 70:1
 t(1;19)(q21;q13) in alveolar rhabdomyosarcoma, 66:43
 t(1;19)(q23;p13) in ALL, 68:65
 t(1;22)(p13;q13) in AML-M7, 67:81; 68:65
 t(2;3)(p11;q27) in lymphoma cell line from liver transplant patient, 71:155
 t(2;3)(q13;p25) in thyroid adenoma, 67:1
 t(2;3)(q35;q11) in meningioma, 66:118
 t(2;4)(p23;q25) in M2, 70:140
 t(2;4)(q32;q35) in ependymoma, 69:151
 t(2;5)(p23;q35) in NHL, 68:65
 t(2;6)(q32.2;q25.3) constitutional in neuroblastoma, 69:166
 t(2;8)(p12;q24) in BL, 68:65
 t(2;8)(q10;q10) in breast cancer, 69:91
 t(2;8)(q21;q24) in carcinoids, 66:33
 t(2;9)(p12;p23) in pre-B ALL, 69:163
 t(2;10)(p25;p12) in ependymoma, 69:151
 t(2;10)(q21.2;q22.1) in leiomyoma, 69:132
 t(2;11)(p21;q23) in MDS, 68:65
 t(2;11)(p23;q22) constitutional in neuroblastoma, 69:166
 t(2;11)(q11.2;p11.2) in germ cell tumor, 68:114
 t(2;11)(q21;q23) in alveolar rhabdomyosarcoma, 66:43
 t(2;13)(p14;q33) in chondromyxoid fibroma, 69:79
 t(2;13)(q32;p12) in chondrosarcoma, 69:79
 t(2;14)(p13;p11) in gastric cancer, 68:42
 t(2;14)(p13;q32) in B-CLL, 68:65
 t(2;15)(q11;q11) in chondroblastoma, 69:79
 t(2;16)(p23;p13) in meningioma, 66:118
 t(2;17)(q13;q25) in nasopharyngeal cancer, 66:12
 t(3;3)(q21;q26) in AML, 68:65
 t(3;3)(q22;q26) in M4 in XYY man, 69:156
 t(3;5)(q21;q31) in AML/MDS, 68:65
 t(3;5)(q25;q34-35) in AML, 68:65
 t(3;6)(p14;p11) in hematologic states, 71:15
 t(3;7)(p21;q11) in esophageal cancer, 70:127
 t(3;8)(p22;q11) in nasopharyngeal cancer, 66:12
 t(3;8)(q27;q12) in well-differentiated LPS, 68:85
 t(3;9)(q27;q22) in chondrosarcoma, 69:79
 t(3;9;22)(p21;q34;q11) variant Ph in CML, 67:50
 t(3;11)(q26;q13) in M4, 69:158
 t(3;12)(p21;q24) in chondrosarcoma, 69:79
 t(3;14)(p21;p11) in colonic polyps, 67:17
 t(3;15)(q13.1;q26) in juvenile CML, 71:67
 t(3;21)(p12;p12) in angiocentric lymphoma, 69:25
 t(3;21)(p14;q22) in AML, 68:65
 t(3;21)(q26;q22) in CML (Ph+), 68:122
 t(3;21)(q26;q22) in MDS, 68:65
 t(4;9;22)(q21;q34;q11) variant Ph in CML, 67:50
 t(4;10)(q21;q22) in leiomyoma, 69:132
 t(4;11)(q21;p14-15) in T-ALL, 69:122
 t(4;11)(q21;q23) in ALL, 68:65
 t(4;11)(q27;q23) in esophageal cancer, 70:127
 t(4;11;13)(q21;q23;q12-14) in ALL, 69:153
 t(4;12)(q21;p13) in breast cancer, 65:64
 t(4;13)(p14;q32) in clear cell sarcoma of kidney, 66:152
 t(4;21)(p16;q22) in nasopharyngeal cancer, 66:12
 t(5;6)(p13;p23) in biphenotypic leukemia, 69:129
 t(5;7)(q15;q11.2) in thyroid adenoma, 67:1
 t(5;8)(q10;q10) in breast cancer, 69:91
 t(5;8)(q34-35;q1) in nasopharyngeal cancer, 66:12
 t(5;9;22)(q13;q34;q11) in CML, 65:107
 t(5;10)(q12;q26) in M2, 71:119
 t(5;12)(q23;p13) in secondary osteosarcoma, 69:35
 t(5;12)(q31;p12) in CML and CMMoL, 65:7
 t(5;13)(p11;q11) in dermatofibrosarcoma protuberans, 67:149
 t(5;14)(q31;q32) in ALL, 68:65
 t(5;16)(q33;q22) in AML, 68:65
 t(5;17)(q11;q11) in sAML, 70:1
 t(5;19)(q11;p13) in immunoblastic lymphoma, 69:25
 t(5;19)(q13;q13) in thyroid adenoma, 67:1
 t(6;6)(q21;p21) in carcinoids, 66:33
 t(6;7)(p23;p14) in M4, 71:119
 t(6;7)(p25;q11.23) in an adrenocortical tumor, 68:78
 t(6;7)(q11;q11) in gastric cancer, 68:42
 t(6;8)(q12;q13.1) in uveal melanoma, 66:47
 t(6;8)(q21;q13) in breast cancer, 69:91
 t(6;9)(p12;p23) in uveal melanoma, 66:47
 t(6;9)(p22.3;q34) in RAEB-t, 69:74
 t(6;9)(p23;q34) in AML, 68:65
 t(6;9;22)(p21;q34;q11) variant Ph in CML, 67:50
 t(6;10)(p21;q22) in leiomyoma, 69:132
 t(6;10)(q21.1;q22) in leiomyoma, 69:132
 t(6;11)(p21.3;q13) in M2, 65:53
 t(6;11)(q15;q21) in breast cancer, 69:91
 t(6;11)(q26-27;q23) in ALL and ANLL, 65:125
 t(6;11)(q27;q23) in AML, 68:65

- t(6;12)(q11;p11) in nasopharyngeal cancer, 66:12
 t(6;13)(p21;q11) in nasopharyngeal cancer, 66:12
 t(6;13)(p23;q14) in childhood MDS, 70:17
 t(7;7)(p13;q21) in Wilms tumor, 69:57
 t(7;8)(p22;q21) in gastric cancer, 68:42
 t(7;11)(p15;p15) in AML, 68:65
 t(7;11)(p15;p15) in AML with low LAP, 68:143
 t(7;11)(p?15;p?13) in esophageal cancer, 70:127
 t(7;11)(q11;q24) in M7 in child, 66:75
 t(7;11)(q35;p13) in T-ALL, 68:65
 t(7;14)(p15;q32) in AML, 68:65
 t(7;14)(q35-36;q11) in ALL, 68:65
 t(7;22)(q36;q11) variant Ph in CML, 67:50
 t(8;9)(p11;q34) in MPD, 68:65
 t(8;9)(p21;q12) in germ cell tumor, 68:114
 t(8;9)(q10;q10) in breast cancer, 69:91
 t(8;9)(q22;q34) in MPD, 68:65
 t(8;11)(q10;q10) in breast cancer, 69:91
 t(8;11)(q22.1;q21) constitutional in neuroblastoma, 69:166
 t(8;11)(q24;q21) in B-lymphoma cell line, 70:62
 t(8;11)(q24;q22)t(8;14)(p21-22;q11) in T-lymphoma, 70:71
 t(8;12)(p21-22;q13) in ALL, 68:65
 t(8;12)(p23;q21) in myeloid metaplasia, 71:183
 t(8;13)(p11.2;q12) in T-lymphoma, 65:71
 t(8;13)(q10;q10) in breast cancer, 69:91
 t(8;14)(q11;q32) in ALL, 67:55; 68:65
 t(8;14)(q11;q32) in ALL in Down syndrome, 70:148
 t(8;14)(q24;q11) in T-ALL, 68:65
 t(8;14)(q24;q32) in ALL-L3/BL, 68:65
 t(8;14)(q24;q32) in L3, 71:178
 t(8;16)(p11;p13) in AML, 68:65
 t(8;17)(q22;p13) in nasopharyngeal cancer, 66:12
 t(8;21)(q22;q22) in M2, 65:53; 71:119
 t(8;21)(q22;q22) in AML-M2, 68:65
 t(8;21)(q22;q22) in PV prior to acute leukemia, 70:125
 t(8;22)(p13;q13.3) in leiomyoma, 67:59
 t(8;22)(q24;q11) in ALL-L3/BL, 68:65
 t(8;22)(q24;q11) in CLL, 65:157
 t(9;1;9)(p12;p11 p43;p11) in thyroid cancer, 67:117
 t(9;11)(p21-22;q23) in AML, 68:65
 t(9;11)(p22;q23) in M4, 71:119
 t(9;11;14)(p22;q23;q24) in M5a, 71:176
 t(9;12)(p11;p12) in ALL, 68:65
 t(9;12)(q12;q24) in secondary osteosarcoma, 69:35
 t(9;13)(p13;q14) in gastric cancer, 68:42
 t(9;14)(q11;p11) in gastric cancer, 68:42
 t(9;15)(q10;q10) in lung cancer, 69:1
 t(9;22)(p22;p11.2) in chondrosarcoma, 69:79
 t(9;22)(q34;q11) in CML, 66:103
 t(9;22)(q34;q11) in MPD/CML/ALL/AML, 68:65
 t(9;22;10)(q34;q11;q11) variant Ph in CML, 67:50
 t(9;22;12)(q34;q11;q11) variant Ph in CML, 67:50
 t(10;11)(p12-14;q13-21) in AML, 68:66
 t(10;11;12)(q22;p13;q14) in leiomyoma, 69:132
 t(10;12)(p14-15;q13) in benign epithelial tumor of breast, 69:68
 t(10;12)(q22;q13) in leiomyoma, 69:132
 t(10;12)(q25;q14) in leiomyoma, 69:132
 t(10;14)(q24;q11) in T-ALL, 68:66
 t(10;15)(q22;q26) in colonic polyps, 67:17
 t(10;17)(p13;q12-21) in AML, 68:66
 t(11;9)(9;22)(q23;p22q34;q11) in CML, 68:131
 t(11;11)(p15;q13) in chondrosarcoma, 69:79
 t(11;11)(p15;q23) in M5, 70:1
 t(11;11)(q23;q25) in AML, 68:66
 t(11;12)(q11;p11) in chondrosarcoma, 69:79
 t(11;12)(q23;q21) in leiomyoma, 69:132
 t(11;13)(p13;q12) in gastric cancer, 68:42
 t(11;14)(p13;q11) in T-ALL, 68:66
 t(11;14)(q13;q32) in NHL/CLD, 68:66
 t(11;15)(p14;q22) in osteochondroma, 69:79
 t(11;16)(q13;q22) in M4, 71:119
 t(11;17)(p10;q10) in LPS, 68:85
 t(11;17)(q23;q21) in AML, 68:66
 t(11;17)(q23;q21) in M5, 71:173
 t(11;17)(q23;q25) in AML, 68:66
 t(11;19)(q23;p13) in AML/ALL, 68:66
 t(11;20)(p12;p13) in breast cancer, 69:91
 t(11;20)(p15;q11) in AML, 68:66
 t(11;22)(p13;q11.2) in desmoplastic small round-cell tumors, 69:17
 t(11;22)(p15;q11) variant Ph in CML, 67:50
 t(11;22)(q24;q12) in Ewing sarcoma, 68:1
 t(11;22)(q24;q12) in mesenchymal chondrosarcoma, 71:144
 t(11;22)(q24;q12) in small round cell tumors, 66:167; 68:1
 t(12;13) in secondary MDS, 70:117
 t(12;13)(q24;q13-14) in infantile fibrosarcoma, 71:94
 t(12;13)(p12;q12) in chondrosarcoma, 69:79
 t(12;13)(q14-15;q34) in endometrial polyp, 68:32
 t(12;13;15)(q13;q13;p11) in M2, 71:119
 t(12;14)(p13;q24) in prostate cancer, 66:97
 t(12;14)(q13;q32) in MDS, 65:76
 t(12;14)(q13-14;q24) in benign epithelial tumor of breast, 69:68
 t(12;14)(q24;q32) in AML, 68:66
 t(12;15)(q13;q11) in enchondroma, 69:79
 t(12;16)(q13;q24) in fibrolipoma, 67:145
 t(12;17)(p12-13;q12) in ALL, 68:66
 t(12;19)(q13;q13.3) in hemangiopericytoma, 71:151
 t(12;21)(q23;q22) in MDS with eosinophilia, 68:95
 t(12;22)(p13;q13) in M7, 65:81
 t(12;22)(q11;q11) in germ cell tumor, 68:114
 t(12;22)(q13;q12) in clear cell sarcoma of tendons, 66:165
 t(13;15)(q10;q10) in PV, 65:54
 t(13;19)(q14;q13) in gastric cancer, 68:42
 t(13;22)(q34;q11) variant Ph in CML, 67:50
 t(14;15)(p11;p11) in sAML, 70:1
 t(14;17)(q32;q23) in CLD, 68:66
 t(14;18)(q32;q21) in B-lymphoma cell line, 70:62
 t(14;18)(q32;q21) in lymphoma, 68:7
 t(14;18)(q32;q21) in L3 ALL, 65:177
 t(14;18)(q32;q21) in NHL, 68:66
 t(14;19)(q32;q13) in NHL, 68:66

- t(14;22)(q32;q11) in ALL/CLD, 68:66
 t(15;17)(q22;q11-12) in AML-M3, 68:66
 t(15;17)(q24;q21) in M4, 70:79
 t(15;17;18)(q21;q12;q12) in APL, 69:113
 t(15;18)(q15;p11.2) in germ cell tumor, 68:114
 t(15;20)(p11;p11) in osteoblastoma, 69:65
 t(15;20)(q10;q10) in colonic polyps, 67:7
 t(16;16)(p13;q22) in AML-M4EO/MDS, 68:66
 t(16;21)(p11;q22) in AML, 68:66
 t(16;21)(p11;q22) in M1, 70:144
 t(16;21)(p11.1;q22) in M5b, 70:99
 t(16;22)(q24;q11) variant Ph in CML, 67:50
 t(17;19)(p11.2;q13.3) in thyroid adenoma, 67:1
 t(17;20)(p11-12;q11) in osteoblastoma, 69:65
 t(17;22)(q25;q11) variant Ph in CML, 67:50
 t(18;22)(p11.2;q13.1) in thyroid adenoma, 67:1
- Trisomy**
- FISH studies in various disorders, 66:73
 - in AML, 65:53; 69:139
 - in hematologic disorders, 68:60
 - in MDS, 65:53
 - meiotic origin of trisomic tumors, 70:112
 - trisomic neoplasms, 70:112
 - +4 and dmin in ANLL, 69:41
 - +4 in ALL, 65:115
 - +4 in hematologic disorders, 69:139; 70:152; 71:71
 - +4 in Kuwaiti case, 68:147
 - +4 in M1 (Brazilian case, Chinese case), 68:82; 69:139
 - +4 in M2, 71:71
 - +4 in M4, 65:115; 68:147; 70:152
 - +7 in normal lung and kidney cells, 66:100
 - +8 in AML and cell-lineage, 70:1
 - +8 in breast cancer, 65:64
 - +8 in MDS, 70:120
 - +8 in myeloid metaplasia, 71:183
 - +8 in uveal melanoma, 66:47
 - +11,+17,+20 in fibrosarcoma (congenital), 65:152
 - +12 in L3, 71:178
 - +12 in ovarian thecoma, 71:180
 - +13 in MDS progressing to M1, 69:136
 - +21 mosaicism and ALL, 66:70
- Tumor(s)**
- biphasic tumors, 66:147
 - chromosome changes, 68:60
 - chromosome number in tumors (metaphase and interphase), 66:156
 - field inversion gel electrophoresis of DNA, 65:68
 - FISH studies of individual cells, 68:104
 - homozygous deletions in, 65:83
 - PCR and biopsies, 65:83
 - recovery of high-molecular-weight DNA, 65:68
 - unique sequences and structural anomalies in tumors, 66:144
 - uterine, 67:59
- Uterine tumors**
- leiomyoma, 67:59; 69:132; 71:1
 - chromosome 7 in leiomyoma, 67:59; 71:1
- Viruses**
- Epstein-Barr in Burkitt lymphoma, 67:90
 - integration near breakpoint in t(11;19), 67:90
- von Hippel-Lindau disease**
- molecular cytogenetics, 66:163
- Waldenström macroglobulinemia**
- SCE in, 66:63
 - SCE in bone marrow, 66:63
- Wilms tumor**
- in Li-Fraumeni syndrome, 67:133
 - telomeric associations, 69:141
 - telomeric fusions in, 69:141
 - t(7;7)(p13;q21), 69:57
- Wiskott-Aldrich syndrome**
- lack of chromosome instability, 69:22
- X-chromosome**
- der(X) in ependymoma, 69:146
 - involvement in renal cancer, 65:1
 - X in breast cancer, 65:64
 - X in leiomyoma, 69:134
- X-ray chromatid damage**
- DNA repair, 70:25
 - in Alzheimer disease, 70:25
 - in Down syndrome, 70:25
- Y-chromosome**
- t(Y;1)(q12;q21) in MDS, 70:155
 - t(Y;1)(q12;q21) in M2 after MDS, 70:136
 - XY and M4, 69:156
 - Y in adrenocortical tumors, 68:78
 - Y in alveolar rhabdomyosarcoma, 66:43
 - Y in AML, 65:53
 - Y in MDS, 67:71
 - Y in M2 with t(8;21), 70:6
 - Y in prostate BPH, 68:126
 - Y in prostate cancer, 66:93
 - Y in prostate cells but not in stroma, 66:131
 - Y in pituitary adenoma, 69:118
 - Y in Sertoli tumor, 65:104
- Yeast Artificial Chromosome (YAC)**
- in renal cell tumor, 77:164
 - spanning t(X;1) in renal tumor, 77:164

